Disease on EC 1.17.4.2 - ribonucleoside-triphosphate reductase (thioredoxin)

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acidosis, Lactic
Mitochondrial DNA depletion syndrome due to mutations in the RRM2B gene.
Acute Kidney Injury
Clofarabine-induced kidney toxicity.
Adenocarcinoma
Adenovirus-mediated ribonucleotide reductase R1 gene therapy of human colon adenocarcinoma.
Alterations of ribonucleotide reductase activity following induction of the nitrite-generating pathway in adenocarcinoma cells.
Early loss of the tyrosyl radical in ribonucleotide reductase of adenocarcinoma cells producing nitric oxide.
Gemcitabine sensitivity-related mRNA expression in endoscopic ultrasound-guided fine-needle aspiration biopsy of unresectable pancreatic cancer.
Histology-Related Associations of ERCC1, RRM1, and TS Biomarkers in Patients with Non-Small-Cell Lung Cancer: Implications for Therapy.
Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells.
Inhibition of ribonucleotide reductase by nitric oxide derived from thionitrites: reversible modifications of both subunits.
Intratumour variation of biomarker expression by immunohistochemistry in resectable non-small cell lung cancer.
Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy.
Plk1 inhibition enhances the efficacy of gemcitabine in human pancreatic cancer.
Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma.
Ribonucleotide reductase immunoreactivity in adenocarcinoma cells and malignant or reactive mesothelial cells in serous effusions.
Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma.
Ribonucleotide reductase subunit one as gene therapy target: commentary re: M-Y. Cao et al., Adenovirus-mediated ribonucleotide reductase R1 gene therapy of human colon adenocarcinoma. Clin. Cancer Res., 9: 4304-4308, 2003.
Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer.
RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine.
Targeting ribonucleotide reductase M2 subunit by small interfering RNA exerts anti-oncogenic effects in gastric adenocarcinoma.
Adenocarcinoma of Lung
Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine.
adenosine deaminase deficiency
Adenosine deaminase impairment and ribonucleotide reductase activity and levels in HeLa cells.
Characterization of a cultured human T-cell line with genetically altered ribonucleotide reductase activity. Model for immunodeficiency.
Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency.
Effects of deoxyadenosine on ribonucleotide reductase in adenosine deaminase-deficient lymphocytes.
Adrenal Cortex Neoplasms
Ribonucleotide reductase large subunit (RRM1) gene expression may predict efficacy of adjuvant mitotane in adrenocortical cancer.
African Swine Fever
Gel retardation analysis of ribonucleotide reductase gene expression in African swine fever virus.
Induction of ribonucleotide reductase activity in cells infected with African swine fever virus.
The sequences of the ribonucleotide reductase genes from African swine fever virus show considerable homology with those of the orthopoxvirus, vaccinia virus.
Anemia
The effects of lithium in reversing hydroxyurea induced suppression of hematopoietic progenitor cells in vitro using retroviral infected long-term marrow cultures.
Trimidox-mediated morphological changes during erythroid differentiation is associated with the stimulation of hemoglobin and F-cell production in human K562 cells.
Utility of hydroxyurea in mast cell activation syndrome.
Anemia, Pernicious
Leukocyte ribonucleotide reductase: studies in normal subjects and in subjects with leukemia or pernicious anemia.
Anemia, Sickle Cell
Enhancement of hemoglobin and F-cell production by targeting growth inhibition and differentiation of K562 cells with ribonucleotide reductase inhibitors (didox and trimidox) in combination with streptozotocin.
Hydroxyurea induces de novo copy number variants in human cells.
Resveratrol, a natural dietary phytoalexin, possesses similar properties to hydroxyurea towards erythroid differentiation.
The effects of lithium in reversing hydroxyurea induced suppression of hematopoietic progenitor cells in vitro using retroviral infected long-term marrow cultures.
The in vivo toxicity of hydroxyurea depends on its direct target catalase.
Trimidox-mediated morphological changes during erythroid differentiation is associated with the stimulation of hemoglobin and F-cell production in human K562 cells.
Utility of hydroxyurea in mast cell activation syndrome.
Arthritis, Infectious
Ribonucleotide reductase class III, an essential enzyme for the anaerobic growth of Staphylococcus aureus, is a virulence determinant in septic arthritis.
Ataxia
A series of N-carbamoyloxyurea resistant cell lines with alterations in ribonucleotide reductase: lack of coordination in pyrimidine and purine reductase activity.
Ataxia Telangiectasia
Ataxia-telangiectasia mutated kinase regulates ribonucleotide reductase and mitochondrial homeostasis.
ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways.
Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints.
Atherosclerosis
Ribonucleotide reductase inhibitors reduce atherosclerosis in a double-injury rabbit model.
Biliary Tract Neoplasms
Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer.
Brain Neoplasms
Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase.
Combined effects of temozolomide and the ribonucleotide reductase inhibitors didox and trimidox in malignant brain tumor cells.
Experimental combination chemotherapy with thymidylate synthetase and ribonucleotide reductase inhibitors.
PET: brain tumor biochemistry.
Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy.
Breast Neoplasms
An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients.
Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors of prognosis in patients with non-small cell lung cancer who received cisplatin-based adjuvant chemotherapy: A prospective study.
Are we ready to use biomarkers for staging, prognosis and treatment selection in early-stage non-small-cell lung cancer?
Autophagy induction causes a synthetic lethal sensitization to ribonucleotide reductase inhibition in breast cancer cells.
Biomarker expression and druggable gene alterations for development of an appropriate therapeutic protocol for pulmonary adenosquamous carcinoma.
Differential expression of ERCC-1 in the primary tumors and metastatic lymph nodes of patients with non-small cell lung cancer adenocarcinoma.
ERCC1 and BRCA1 mRNA expressions are associated with clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
Establishment of human pancreatic cancer gemcitabine?resistant cell line with ribonucleotide reductase overexpression.
Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I-III Non-Small Cell Lung Cancer.
Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine.
Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.
How close are we to customizing chemotherapy in early non-small cell lung cancer?
Inhibition of growth of human breast carcinoma cells by an antisense oligonucleotide targeted to the transferrin receptor gene.
Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer.
Phase II trial of didox in advanced breast cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee.
Prediction of a Side Effect and Efficacy of Adjuvant Chemotherapy with Gemcitabine for Post Operative Patient of Pancreatic Cancer by a Genetic Polymorphism Analysis.
Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy.
Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer.
Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: comparison of real-time reverse transcription-PCR vs. relative quantification reverse transcription-PCR utilizing DNA sequencer analysis of PCR products.
Reactions of purines-containing butenolides with L-cysteine or N-acetyl-L-cysteine as model biological nucleophiles: a potent mechanism-based inhibitor of ribonucleotide reductase caused apoptosis in breast carcinoma MCF7 cells.
Ribonucleotide reductase subunit M2B deficiency leads to mitochondrial permeability transition pore opening and is associated with aggressive clinicopathologic manifestations of breast cancer.
RRM1 gene expression in peripheral blood is predictive of shorter survival in Chinese patients with advanced non-small-cell lung cancer treated by gemcitabine and platinum.
RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC.
Sequence analysis of the large and small subunits of human ribonucleotide reductase.
Targeting ribonucleotide reductase M2 and NF-?B activation with Didox to circumvent tamoxifen resistance in breast cancer.
XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression.
[Silencing RRM1 gene reverses paclitaxel resistance in human breast cancer cell line MCF- 7/R by inducing cell apoptosis].
Burkitt Lymphoma
Azinyl and diazinyl hydrazones derived from aryl N-heteroaryl ketones: synthesis and antiproliferative activity.
Eradication of latent Epstein-Barr virus by hydroxyurea alters the growth-transformed cell phenotype.
Carcinogenesis
Bioinformatics analysis revealing prognostic significance of RRM2 gene in breast cancer.
Conditional expression of 15-lipoxygenase-1 inhibits the selenoenzyme thioredoxin reductase: modulation of selenoproteins by lipoxygenase enzymes.
Design, synthesis and cytotoxic evaluation of o-carboxamido stilbene analogues.
DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer.
Metastasis-suppressing potential of ribonucleotide reductase small subunit p53R2 in human cancer cells.
Response to gemcitabine-platinum chemotherapy by single nucleotide polymorphisms of RRM1 and ERCC1 genes in patients with non-small-cell lung cancer.
Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad?
Setd2 deficiency impairs hematopoietic stem cell self-renewal and causes malignant transformation.
The expression of ribonucleotide reductase m2 in the carcinogenesis of uterine cervix and its relationship with clinicopathological characteristics and prognosis of cancer patients.
Carcinoma
A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma.
Antitumor and radiosensitizing effects of (E)-2'-deoxy-2'-(fluoromethylene) cytidine, a novel inhibitor of ribonucleoside diphosphate reductase, on human colon carcinoma xenografts in nude mice.
Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector.
Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection.
Different pathways of 5-fluorouracil metabolism after continuous venous or bolus injection in patients with colon carcinoma: possible predictive value of thymidylate synthetase mRNA and ribonucleotide reductase for 5-fluorouracil sensitivity.
Effect of ribonucleotide reductase inhibitors on the growth of human colon carcinoma HT-29 cells in culture.
Expression of ribonucleotide reductase after ionizing radiation in human cervical carcinoma cells.
Gemcitabine resistance mediated by ribonucleotide reductase M2 in lung squamous cell carcinoma is reversed by GW8510 through autophagy induction.
Histology-Related Associations of ERCC1, RRM1, and TS Biomarkers in Patients with Non-Small-Cell Lung Cancer: Implications for Therapy.
Hydroxyurea decreases gemcitabine resistance in pancreatic carcinoma cells with highly expressed ribonucleotide reductase.
Inhibition of ribonucleotide reductase and growth of human colon carcinoma HT-29 cells and mouse leukemia L1210 cells by N-hydroxy-N'-aminoguanidine derivatives.
Metabolism and ribonucleotide reductase inhibition of (E)-2'-deoxy-2'-(fluoromethylene)cytidine, MDL 101,731, in human cervical carcinoma HeLa S3 cells.
Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161).
Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy.
Purine enzymology of human colon carcinomas.
Quantitation of G0 and G1 phase cells in primary carcinomas. Antibody to M1 subunit of ribonucleotide reductase shows G1 phase restriction point block.
Ribonucleotide reductase M2 is a promising molecular target for the treatment of oral squamous cell carcinoma.
Ribonucleotide reductase subunit M1 assessed by quantitative double-fluorescence immunohistochemistry predicts the efficacy of gemcitabine in biliary tract carcinoma.
Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patients.
Ribonucleotide reductase subunit M1 is a possible chemoresistance marker to gemcitabine in biliary tract carcinoma.
Ribonucleotide reductase subunit M2 as a novel target for clear-cell renal cell carcinoma.
Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas.
Ribonucleotide reductase subunit M2 predicts survival in subgroups of patients with non-small cell lung carcinoma: effects of gender and smoking status.
Structural aspects of N-hydroxy-N'-aminoguanidine derivatives as inhibitors of L1210 cell growth and ribonucleotide reductase activity.
Synergistic enhancement of herpes simplex virus thymidine kinase/ganciclovir-mediated cytoxicity by hydroxyurea.
The relationship between the antitumor activity and the ribonucleotide reductase inhibitory activity of (E)-2'-deoxy-2'-(fluoromethylene) cytidine, MDL 101,731.
The ribonucleotide reductase inhibitor trimidox induces c-myc and apoptosis of human ovarian carcinoma cells.
[Studies on the thymidine-triphosphate synthesis in malignant tumors. I. Effects of thymidine on deoxyribonucleoside triphosphate pools and deoxyribonucleic acid synthesis (author's trans)]
[Studies on the thymidine-triphosphate synthesis in malignant tumors. II. Effect of hyperthermia, Vitamin K and Cytotoxic agents (author's transl)]
Carcinoma, Ductal
Identification of genes expressed in premalignant breast disease by microscopy-directed cloning.
Carcinoma, Ehrlich Tumor
Properties of N-hydroxy-N'-aminoguanidine derivatives as inhibitors of mammalian ribonucleotide reductase.
Quenching of tyrosine radicals of M2 subunit from ribonucleotide reductase in tumor cells by different antitumor agents: an EPR study.
Ribonucleotide reductase activity during the growth of Ehrlich ascites tumor.
Ribonucleotide reductase and DNA synthesis in Ehrlich ascites tumor cells.
Ribonucleotide reductase in melanoma tissue. EPR detection in human amelanotic melanoma and quenching of the tyrosine radical by 4-hydroxyanisole.
Carcinoma, Hepatocellular
Cytotoxic and cell kinetic effects of 3,4,5-trihydroxybenzohydroxamic acid (VF 122) in hepatoma 3924A cells.
High expression of ribonucleotide reductase subunit M2 correlates with poor prognosis of hepatocellular carcinoma.
Inhibition of hepatocellular carcinoma growth using immunoliposomes for co-delivery of adriamycin and ribonucleotide reductase M2 siRNA.
Relationship between pyridine nucleotide levels and ribonucleotide reductase activity in Yoshida ascites hepatoma AH130.
Ribonucleotide reductase and cell proliferation. I. Variations of ribonucleotide reductase activity with tumor growth rate in a series of rat hepatomas.
Ribonucleotide reductase M2B inhibits cell migration and spreading by early growth response protein 1-mediated phosphatase and tensin homolog/Akt1 pathway in hepatocellular carcinoma.
Ribonucleotide reductase subunit M2 can be new molecular target and prognostic biomarker of hepatocellular carcinoma.
Utilizing alpha-fetoprotein expression to enhance oncolytic viral therapy in hepatocellular carcinoma.
[Mitochondrial thymidine kinase and ribonucleotide reductase from rat liver and rat hepatoma 27]
Carcinoma, Intraductal, Noninfiltrating
Identification of genes expressed in premalignant breast disease by microscopy-directed cloning.
Carcinoma, Non-Small-Cell Lung
(18)F-fluorodeoxyglucose Uptake with Expression of Excision Repair Cross-complementary Group 1 and Ribonucleotide Reductase Subunit M1 in Non-small Cell Lung Cancer.
An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines.
Association between epidermal growth factor receptor mutations and the expression of excision repair cross-complementing protein 1 and ribonucleotide reductase subunit M1 mRNA in patients with non-small cell lung cancer.
Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy.
Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene.
ERCC1 and BRCA1 mRNA expressions are associated with clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis.
ERCC1 mRNA expression is associated with the clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I-III Non-Small Cell Lung Cancer.
Expression of RRM1 and its correlation with sensitivity to gemcitabine-based chemotherapy in advanced nasopharyngeal carcinoma.
Expression status of ribonucleotide reductase small subunits hRRM2/p53R2 as prognostic biomarkers in stage I and II non-small cell lung cancer.
Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancer.
Molecular predictors of response to chemotherapy in non-small cell lung cancer.
Molecular Targets of Gemcitabine Action: Rationale for Development of Novel Drugs and Drug Combinations.
Multiplex real-time PCR for RRM1, XRCC1, TUBB3 and TS mRNA for prediction of response of non-small cell lung cancer to chemoradiotherapy.
P53R2, p53 inducible ribonucleotide reductase gene, correlated with tumor progression of non-small cell lung cancer.
Polymorphisms of the ribonucleotide reductase M1 gene and sensitivity to platin-based chemotherapy in non-small cell lung cancer.
Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer.
Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells.
Predictors of biomarkers guiding targeted therapeutic strategies in locally advanced lung cancer.
Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy.
Prognostic significance of the mRNA expression of ERCC1, RRM1, TUBB3 and TYMS genes in patients with non-small cell lung cancer.
Prognostic value of ERCC1, RRM1, and TS proteins in patients with resected non-small cell lung cancer.
Prognostic value of ribonucleotide reductase subunit M1 (RRM1) in non-small cell lung cancer: A meta-analysis.
Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine.
RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer.
RRM1 expression and the clinicopathological characteristics of patients with non-small cell lung cancer treated with gemcitabine.
Staurosporine increases toxicity of gemcitabine in non-small cell lung cancer cells: role of protein kinase C, deoxycytidine kinase and ribonucleotide reductase.
The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC).
The prognostic value of ERCC1 and RRM1 gene expression in completely resected non-small cell lung cancer: tumor recurrence and overall survival.
[Differential expressions of MDR-1, RRM-1, EGFR and ERCC-1 in primary tumors and metastatic lymph nodes of NSCLC patients].
[Expression and predictive role of excision repair cross complementation group 1, ribonucleotide reductase subunit M1, and ?-tubulin3 in postoperative patients with non-small cell lung cancer receiving adjuvant chemotherapy]
[Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines]
[Relationship between the efficacy of gemcitabine/cisplatin adjuvant chemotherapy and RRM1 protein expression in postoperative NSCLC patients].
Carcinoma, Ovarian Epithelial
Identification of ribonucleotide reductase M2 as a potential target for pro-senescence therapy in epithelial ovarian cancer.
Carcinoma, Renal Cell
Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161).
Ribonucleotide reductase subunit M2 as a novel target for clear-cell renal cell carcinoma.
Carcinoma, Squamous Cell
Gemcitabine resistance mediated by ribonucleotide reductase M2 in lung squamous cell carcinoma is reversed by GW8510 through autophagy induction.
Histology-Related Associations of ERCC1, RRM1, and TS Biomarkers in Patients with Non-Small-Cell Lung Cancer: Implications for Therapy.
Loss of the tyrosyl radical in mouse ribonucleotide reductase by (-)-epicatechin.
Ribonucleotide reductase M2 is a promising molecular target for the treatment of oral squamous cell carcinoma.
Chickenpox
Ribonucleotide reductase induced by varicella zoster virus. Characterization, and potentiation of acyclovir by its inhibition.
Studying protein complexes by the yeast two-hybrid system.
Synergistic topical therapy by acyclovir and A1110U for herpes simplex virus induced zosteriform rash in mice.
Cholangiocarcinoma
Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy.
Ribonucleotide reductase M1 expression in intrahepatic cholangiocarcinoma.
Choriocarcinoma
[Effect of antisense oligodeoxynucleotide of small subunit component of human ribonucleotide reductase on human choriocarcinoma cell line in vitro]
Classical Swine Fever
Role of viral proteins and concanavalin A in in vitro replication of pseudorabies virus in porcine peripheral blood mononuclear cells.
Colonic Neoplasms
E2F4 and ribonucleotide reductase mediate S-phase arrest in colon cancer cells treated with chlorophyllin.
Interferon augments the cytotoxicity of hydroxyurea without enhancing its activity against the M2 subunit of ribonucleotide reductase: effects in wild-type and resistant human colon cancer cells.
Novel resveratrol analogs induce apoptosis and cause cell cycle arrest in HT29 human colon cancer cells: inhibition of ribonucleotide reductase activity.
Purine enzymology of human colon carcinomas.
Reverse transcriptase template switching during reverse transcriptase-polymerase chain reaction: artificial generation of deletions in ribonucleotide reductase mRNA.
Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer.
Stable suppression of the R2 subunit of ribonucleotide reductase by R2-targeted short interference RNA sensitizes p53(-/-) HCT-116 colon cancer cells to DNA-damaging agents and ribonucleotide reductase inhibitors.
Colorectal Neoplasms
CREB1 directly activates the transcription of ribonucleotide reductase small subunit M2 and promotes the aggressiveness of human colorectal cancer.
E2F1 promote the aggressiveness of human colorectal cancer by activating the ribonucleotide reductase small subunit M2.
Emerging roles of the ribonucleotide reductase M2 in colorectal cancer and ultraviolet-induced DNA damage repair.
Physical interaction between human ribonucleotide reductase large subunit and thioredoxin increases colorectal cancer malignancy.
Repositioning of a cyclin-dependent kinase inhibitor GW8510 as a ribonucleotide reductase M2 inhibitor to treat human colorectal cancer.
Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers.
Ribonucleotide reductase small subunit M2B prognoses better survival in colorectal cancer.
Upregulation of enzymes metabolizing 5-fluorouracil in colorectal cancer.
Deficiency Diseases
Adenosine deaminase impairment and ribonucleotide reductase activity and levels in HeLa cells.
Cockayne's syndrome fibroblasts are characterized by hypersensitivity to deoxyguanosine and abnormal DNA precursor pool metabolism in response to deoxyguanosine or ultraviolet light.
Dehydration
Dehydration of ribonucleotides catalyzed by ribonucleotide reductase: the role of the enzyme.
Demyelinating Diseases
A monoclonal antibody against HSV type 1 ribonucleotide reductase cross-reacts with the P0 protein of peripheral nerve myelin.
Dental Caries
Analysis of a genomic segment of white spot syndrome virus of shrimp containing ribonucleotide reductase genes and repeat regions.
Ribonucleotide reductase of shrimp white spot syndrome virus (WSSV): expression and enzymatic activity in a baculovirus/insect cell system and WSSV-infected shrimp.
Sequencing and amplified restriction fragment length polymorphism analysis of ribonucleotide reductase large subunit gene of the white spot syndrome virus in blue crab (Callinectes sapidus) from American Coastal Waters.
Transcriptional analysis of the ribonucleotide reductase genes of shrimp white spot syndrome virus.
Endocarditis
Streptococcus sanguinis class Ib ribonucleotide reductase: high activity with both iron and manganese cofactors and structural insights.
Endometrial Neoplasms
[Effect of cinobufotalin on growth of xenograft of endometrial carcinoma cell line ishikawa in nude mouse and its impact on RRM2 expression].
Escherichia coli Infections
Correction for Dreux et al., Ribonucleotide Reductase Repressor NrdR as a Novel Regulator for Motility and Chemotaxis during Adherent-Invasive Escherichia coli Infection.
Ribonucleotide reductase NrdR as a novel regulator for motility and chemotaxis during adherent-invasive Escherichia coli infection.
Fibrosarcoma
Involvement of oxidants and oxidant-generating enzyme(s) in tumour-necrosis-factor-alpha-mediated apoptosis: role for lipoxygenase pathway but not mitochondrial respiratory chain.
Focal Epithelial Hyperplasia
Disturbed expression of ribonucleotide reductase and cytokeratin polypeptides in focal epithelial hyperplasia. An immunohistochemical study using monoclonal antibodies.
Fowlpox
Gene translocations in poxviruses: the fowlpox virus thymidine kinase gene is flanked by 15 bp direct repeats and occupies the locus which in vaccinia virus is occupied by the ribonucleotide reductase large subunit gene.
Gastrointestinal Neoplasms
Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit.
Genetic Diseases, Inborn
Hydroxyurea attenuates oxidative, metabolic, and excitotoxic stress in rat hippocampal neurons and improves spatial memory in a mouse model of Alzheimer's disease.
Gestational Trophoblastic Disease
[Expression of R2 protein in gestational trophoblastic diseases.]
Glioblastoma
(E)-2'-deoxy-2'-(fluoromethylene) cytidine potentiates radioresponse of two human solid tumor xenografts.
Gallium Maltolate Disrupts Tumor Iron Metabolism and Retards the Growth of Glioblastoma by Inhibiting Mitochondrial Function and Ribonucleotide Reductase.
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
RRM2 promotes the progression of human glioblastoma.
The effect of hydroxyurea on P-glycoprotein/BCRP-mediated transport and CYP3A metabolism of imatinib mesylate.
The role of DNA synthesis inhibition in the cytotoxicity of 2',2'-difluoro-2'-deoxycytidine.
Glioma
MicroRNA-1468-5p inhibits glioma cell proliferation and induces cell cycle arrest by targeting RRM1.
RRM2 is a potential prognostic biomarker with functional significance in glioma.
Gliosarcoma
Synergistic cytotoxicity of the ribonucleotide reductase inhibitor didox (3,4-dihydroxy-benzohydroxamic acid) and the alkylating agent carmustine (BCNU) in 9L rat gliosarcoma cells and DAOY human medulloblastoma cells.
Head and Neck Neoplasms
A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer.
Heart Failure
2-deoxy-ATP enhances contractility of rat cardiac muscle.
Hematologic Neoplasms
Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells.
Effect of clofarabine on apoptosis and DNA synthesis in human epithelial colon cancer cells.
Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies.
Ribonucleotide reductase and thymidine kinase activities in various cultured cell lines derived from hematologic malignancies.
[Multiple skin cancers in a patient treated with hydroxyurea.]
Hepatitis B
Inhibition of hepatitis B virus replication by targeting ribonucleotide reductase M2 protein.
Hepatitis C
Ribonucleotide reductase M2 promotes RNA replication of hepatitis C virus by protecting NS5B protein from hPLIC1-dependent proteasomal degradation.
Hepatoblastoma
The 11p15.5 ribonucleotide reductase M1 subunit locus is not imprinted in Wilms' tumour and hepatoblastoma.
Herpes Genitalis
Therapeutic Mucosal Vaccination of HSV-2 Infected Guinea Pigs with the Ribonucleotide Reductase 2 (RR2) Protein Boosts Antiviral Neutralizing Antibodies and Tissue-Resident CD4+ and CD8+ TRM Cells Associated with Protection Against Recurrent Genital Herpes.
Herpes Labialis
Solar simulator-induced herpes simplex labialis: use in evaluating treatment with acyclovir plus 348U87.
Herpes Simplex
2-Acetylpyridine 5-[(dimethylamino)thiocarbonyl]-thiocarbonohydrazone (A1110U), a potent inactivator of ribonucleotide reductases of herpes simplex and varicella-zoster viruses and a potentiator of acyclovir.
2-Acetylpyridine thiocarbonohydrazones. Potent inactivators of herpes simplex virus ribonucleotide reductase.
A growth and latency compromised herpes simplex virus type 2 mutant (ICP10DeltaPK) has prophylactic and therapeutic protective activity in guinea pigs.
A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells.
A monoclonal antibody against HSV type 1 ribonucleotide reductase cross-reacts with the P0 protein of peripheral nerve myelin.
A novel gene expressed in human keratinocytes with long-term in vitro growth potential is required for cell growth.
A novel human gene similar to the protein kinase (PK) coding domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) codes for a serine-threonine PK and is expressed in melanoma cells.
A single amino acid substitution in the large subunit of herpes simplex virus type 1 ribonucleotide reductase which prevents subunit association.
A solid-phase assay for the binding of peptidic subunit association inhibitors to the herpes simplex virus ribonucleotide reductase large subunit.
A truncated protein kinase domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) expressed in Escherichia coli.
Affinity of synthetic peptides for the HSV-2 ribonucleotide reductase R1 subunit measured with an iodinated photoaffinity peptide.
Affinity purification of active subunit 1 of herpes simplex virus type 1 ribonucleotide reductase exhibiting a protein kinase activity.
An autophosphorylating but not transphosphorylating activity is associated with the unique N terminus of the herpes simplex virus type 1 ribonucleotide reductase large subunit.
An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy.
Analysis of a herpes simplex virus 2 fragment from the open reading frame of the large subunit of ribonucleotide reductase with transcriptional regulatory activity.
Analysis of cyclin-dependent kinase activity after herpes simplex virus type 2 infection.
Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase.
Antiviral activity of a selective ribonucleotide reductase inhibitor against acyclovir-resistant herpes simplex virus type 1 in vivo.
AP-1 cis-response elements are involved in basal expression and Vmw110 transactivation of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10).
ATP and SH3 binding sites in the protein kinase of the large subunit of herpes simplex virus type 2 of ribonucleotide reductase (ICP10).
Augmented therapeutic efficacy of an oncolytic herpes simplex virus type 1 mutant expressing ICP34.5 under the transcriptional control of musashi1 promoter in the treatment of malignant glioma.
Can ribonucleotide reductase be considered as an effective target for developing antiherpes simplex virus type II (HSV-2) compounds?
Characterization of heterosubunit complexes formed by the R1 and R2 subunits of herpes simplex virus 1 and equine herpes virus 4 ribonucleotide reductase.
Characterization of ribonucleotide reductase induction in BHK-21/C13 Syrian hamster cell line upon infection by herpes simplex virus (HSV).
Characterization of the novel protein kinase activity present in the R1 subunit of herpes simplex virus ribonucleotide reductase.
Cloning of a ribonucleotide reductase gene of the herpes simplex virus type 2 strain G.
Combination of mutated herpes simplex virus type 1 (G207 virus) with radiation for the treatment of squamous cell carcinoma of the head and neck.
Crystal structure of the B subunit of Escherichia coli heat-labile enterotoxin carrying peptides with anti-herpes simplex virus type 1 activity.
Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation.
Deletion of the herpes simplex virus type 1 ribonucleotide reductase gene alters virulence and latency in vivo.
Deletion of the varicella-zoster virus large subunit of ribonucleotide reductase impairs growth of virus in vitro.
Deoxyribonucleoside triphosphate pools in synchronized human cells infected with herpes simplex virus types 1 and 2.
Development of HSV-specific CD4+ Th1 responses and CD8+ cytotoxic T lymphocytes with antiviral activity by vaccination with the HSV-2 mutant ICP10DeltaPK.
Disruption of herpes simplex virus ribonucleotide reductase quaternary structure by peptide inhibitors as a novel approach to antiviral therapy.
DNA amplification and neoplastic transformation mediated by a herpes simplex DNA fragment containing cell-related sequences.
Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.
Effect of siRNA on HSV-1 plaque formation and relative expression levels of UL39 mRNA.
Effects of ribonucleotide reductase inhibition on pyrimidine deoxynucleotide metabolism in acyclovir-treated cells infected with herpes simplex virus type 1.
Efficient extracellular production of hybrid E. coli heat-labile enterotoxin B subunits in a marine Vibrio.
Enhanced malignant transformation induced by expression of a distinct protein domain of ribonucleotide reductase large subunit from herpes simplex virus type 2.
Epitope mapping identifies an exposed loop between the unique amino- and conserved carboxy-domains of the large subunit of herpes simplex virus type 1 ribonucleotide reductase.
Evaluation of a peptidomimetic ribonucleotide reductase inhibitor with a murine model of herpes simplex virus type 1 ocular disease.
Evaluation of the antitumor effects of Herpes simplex virus lacking ribonucleotide reductase in a murine retinoblastoma model.
Expression of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is required for virus growth and neoplastic transformation.
Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant.
Functional interaction between fluorodeoxyuridine-induced cellular alterations and replication of a ribonucleotide reductase-negative herpes simplex virus.
Genomic sequences homologous to the protein kinase region of the bifunctional herpes simplex virus type 2 protein ICP10.
Herpes simplex type 1 ribonucleotide reductase. Mechanism studies with inhibitors.
Herpes Simplex Virus 1 (HSV-1) and HSV-2 Mediate Species-Specific Modulations of Programmed Necrosis through the Viral Ribonucleotide Reductase Large Subunit R1.
Herpes simplex virus mediated gene transfer to primate ocular tissues.
Herpes simplex virus ribonucleotide reductase induced in infected BHK-21/C13 cells: biochemical evidence for the existence of two non-identical subunits, H1 and H2.
Herpes simplex virus ribonucleotide reductase mutants are hypersensitive to acyclovir.
Herpes simplex virus ribonucleotide reductase subunit association inhibitors: the effect and conformation of beta-alkylated aspartic acid derivatives.
Herpes simplex virus ribonucleotide reductase: expression in Escherichia coli and purification to homogeneity of a tyrosyl free radical-containing, enzymatically active form of the 38-kilodalton subunit.
Herpes simplex virus specifies two subunits of ribonucleotide reductase encoded by 3'-coterminal transcripts.
Herpes simplex virus type 1 ribonucleotide reductase large subunit: regions of the protein essential for subunit interaction and dimerization.
Herpes simplex virus type 1 ribonucleotide reductase null mutants induce lesions in guinea pigs.
Herpes simplex virus type 1 ribonucleotide reductase: selective and synergistic inactivation by A1110U and its iron complex.
Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant.
Herpes simplex virus type 2 growth and latency reactivation by cocultivation are inhibited with antisense oligonucleotides complementary to the translation initiation site of the large subunit of ribonucleotide reductase (RR1).
Herpes simplex virus type 2: unique biological properties include neoplastic potential mediated by the PK domain of the large subunit of ribonucleotide reductase.
Herpes simplex virus-encoded ribonucleotide reductase: evidence for the dissociation/reassociation of the holoenzyme.
Herpes simplex virus-induced ribonucleotide reductase: development of antibodies specific for the enzyme.
High level expression in 293 cells of the herpes simplex virus type 2 ribonucleotide reductase subunit 2 using an adenovirus vector.
Identification and characterization of an extracellular protease activity produced by the marine Vibrio sp. 60.
Identification and separation of the two subunits of the herpes simplex virus ribonucleotide reductase.
Identification of a herpes simplex virus type 1 polypeptide which is a component of the virus-induced ribonucleotide reductase.
Identification of immediate-early-type cis-response elements in the promoter for the ribonucleotide reductase large subunit from herpes simplex virus type 2.
Identification of ribonucleotide reductase mutation causing temperature-sensitivity of herpes simplex virus isolates from whitlow by deep sequencing.
Identification of structural domains within the large subunit of herpes simplex virus ribonucleotide reductase.
Identification of viral polypeptides involved in pseudorabies virus ribonucleotide reductase activity.
Immediate early and functional AP-1 cis-response elements are involved in the transcriptional regulation of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10).
Immunological characterization of herpes simplex virus type 1 and 2 polypeptide(s) involved in viral ribonucleotide reductase activity.
Improved adenovirus vector provides herpes simplex virus ribonucleotide reductase R1 and R2 subunits very efficiently.
Improved method for the measurement of ribonucleotide reductase activity.
Inactivators of herpes simplex virus ribonucleotide reductase: hematological profiles and in vivo potentiation of the antiviral activity of acyclovir.
Inducible overexpression of a toxic protein by an adenovirus vector with a tetracycline-regulatable expression cassette.
Inhibition of equine herpesvirus type 1 subtype 1-induced ribonucleotide reductase by the nonapeptide YAGAVVNDL.
Inhibition of herpes simplex virus ribonucleotide reductase by synthetic nonapeptides: a potential antiviral therapy.
Inhibition of herpes simplex virus type 1 ribonucleotide reductase by substituted tetrapeptide derivatives.
Intracellular chelation of iron by bipyridyl inhibits DNA virus replication: ribonucleotide reductase maturation as a probe of intracellular iron pools.
Intracellular localisation of herpes simplex virus type 1 ribonucleotide reductase subunits during infection of cultured cells.
Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by upregulating ribonucleotide reductase.
Is ribonucleotide reductase the transforming function of herpes simplex virus 2?
Leucine repeats in the large subunit of herpes simplex virus type 2 ribonucleotide reductase (RR; ICP10) are involved in RR activity and subunit complex formation.
Localization and comparative nucleotide sequence analysis of the transforming domain in herpes simplex virus DNA containing repetitive genetic elements.
Localization of the antigenic sites and intrinsic protein kinase domain within a 300 amino acid segment of the ribonucleotide reductase large subunit from herpes simplex virus type 2.
Manipulation of apoptosis and necroptosis signaling by herpesviruses.
Mechanism of inhibition of herpes simplex virus (HSV) ribonucleotide reductase by a nonapeptide corresponding to the carboxyl terminus of its subunit 2. Specific binding of a photoaffinity analog, [4'- azido-Phe6] HSV H2-6(6-15), to subunit 1.
Mechanism of ribonucleotide reductase from herpes simplex virus type 1. Evidence for 3' carbon-hydrogen bond cleavage and inactivation by nucleotide analogs.
Monoclonal antibody to HSV2 protein as an immunodiagnostic marker in cervical cancer.
Myristylation and polylysine-mediated activation of the protein kinase domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10).
Neutralization of herpes simplex virus ribonucleotide reductase activity by an oligopeptide-induced antiserum directed against subunit H2.
Oligopeptides inhibit the ribonucleotide reductase of herpes simplex virus by causing subunit separation.
Oncolytic viruses and DNA-repair machinery: overcoming chemoresistance of gliomas.
Papillomavirus trans-activator protein E2 activates expression from the promoter for the ribonucleotide reductase large subunit from herpes simplex virus type 2.
Partial purification and characterization of the ribonucleotide reductase induced by herpes simplex virus infection of mammalian cells.
Peptidomimetic inhibitors of herpes simplex virus ribonucleotide reductase with improved in vivo antiviral activity.
Peptidomimetic inhibitors of herpes simplex virus ribonucleotide reductase: a new class of antiviral agents.
Performance and use of a ribonucleotide reductase herpes simplex virus type-specific serological assay.
Polymorphism within the herpes simplex virus (HSV) ribonucleotide reductase large subunit (ICP6) confers type specificity for recognition by HSV type 1-specific cytotoxic T lymphocytes.
Potential for combined therapy with 348U87, a ribonucleotide reductase inhibitor, and acyclovir as treatment for acyclovir-resistant herpes simplex virus infection.
Potentiation of antiherpetic activity of acyclovir by ribonucleotide reductase inhibition.
Production of the R2 subunit of ribonucleotide reductase from herpes simplex virus with prokaryotic and eukaryotic expression systems: higher activity of R2 produced by eukaryotic cells related to higher iron-binding capacity.
Protein kinase activity associated with the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10).
Purification and characterization of recombinant mouse and herpes simplex virus ribonucleotide reductase R2 subunit.
Purification and characterization of the herpes simplex virus type 1 ribonucleotide reductase small subunit following expression in Escherichia coli.
Radiation inactivation of ribonucleotide reductase, an enzyme with a stable free radical.
Rapid sampling of multiple enzyme reactions.
Reconstitution of herpes simplex virus type 1 ribonucleotide reductase activity from the large and small subunits.
Reduction of the tyrosyl radical and the iron center in protein R2 of ribonucleotide reductase from mouse, herpes simplex virus and E. coli by p-alkoxyphenols.
Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5.
Resistance of herpes simplex virus type 1 to peptidomimetic ribonucleotide reductase inhibitors: selection and characterization of mutant isolates.
Retention and expression of the left end subfragment of the herpes simplex virus type 2 BglII N DNA fragment do not correlate with tumorigenic conversion of NIH 3T3 cells.
Review of research leading to new anti-herpesvirus agents in clinical development: valaciclovir hydrochloride (256U, the L-valyl ester of acyclovir) and 882C, a specific agent for varicella zoster virus.
Ribonucleotide reductase activity of synchronized KB cells infected with herpes simplex virus.
Ribonucleotide reductase encoded by herpes simplex virus is a determinant of the pathogenicity of the virus in mice and a valid antiviral target.
Ribonucleotide reductase from herpes simplex virus (types 1 and 2) infected and uninfected KB cells: properties of the partially purified enzymes.
Ribonucleotide reductase induced by herpes simplex type 1 virus. Characterization of a distinct enzyme.
Ribonucleotide reductase induced by herpes simplex virus has a virus-specified constituent.
Ribonucleotide reductase induced by varicella zoster virus. Characterization, and potentiation of acyclovir by its inhibition.
Ribonucleotide reductase of herpes simplex virus type 2 resembles that of herpes simplex virus type 1.
Ribonucleotide reductase: an important enzyme in the replication of herpes simplex virus type 1 and a target for antiviral chemotherapy.
RNA interference inhibits herpes simplex virus type 1 isolated from saliva samples and mucocutaneous lesions.
Role of viral ribonucleotide reductase in the increase of dTTP pool size in herpes simplex virus-infected Vero cells.
Search for multienzyme complexes of DNA precursor pathways in uninfected mammalian cells and in cells infected with herpes simplex virus type I.
Sequence analysis of the UL39, UL38, and UL37 homologues of bovine herpesvirus 1 and expression studies of UL40 and UL39, the subunits of ribonucleotide reductase.
Specific inhibition of herpes virus replication by receptor-mediated entry of an antiviral peptide linked to Escherichia coli enterotoxin B subunit.
Specific inhibition of herpesvirus ribonucleotide reductase by a nonapeptide derived from the carboxy terminus of subunit 2.
Specific inhibition of herpesvirus ribonucleotide reductase by synthetic peptides.
Stress up-regulates neuronal expression of the herpes simplex virus type 2 large subunit of ribonucleotide reductase (R1; ICP10) by activating activator protein 1.
Structural features of ribonucleotide reductase.
Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase.
Structure-function studies of peptides inhibiting the ribonucleotide reductase activity of herpes simplex virus type I.
Study of ribonucleotide reductase in cells infected with six clinical isolates of herpes simplex virus type 2 (HSV-2) with mutations in its larger subunit.
Susceptibility of a herpes simplex virus ribonucleotide reductase null mutant to deoxyribonucleosides and antiviral nucleoside analogs.
Synergistic topical therapy by acyclovir and A1110U for herpes simplex virus induced zosteriform rash in mice.
Synthesis and inhibitory potency of peptides corresponding to the subunit 2 C-terminal region of herpes virus ribonucleotide reductases.
The 140-kDa RR1 protein from both HSV-1 and HSV-2 contains an intrinsic protein kinase activity capable of autophosphorylation but it is transphosphorylation defective.
The antiviral activity of the ribonucleotide reductase inhibitor BILD 1351 SE in combination with acyclovir against HSV type-1 in cell culture.
The bovine viral diarrhea virus (BVDV) NS3 protein, when expressed alone in mammalian cells, induces apoptosis which correlates with caspase-8 and caspase-9 activation.
The critical C-terminus of the small subunit of herpes simplex virus ribonucleotide reductase is mobile and conformationally similar to C-terminal peptides.
The effects of interferon-alpha and acyclovir on herpes simplex virus type-1 ribonucleotide reductase.
The equine arteritis virus induces apoptosis via caspase-8 and mitochondria-dependent caspase-9 activation.
The herpes simplex virus ribonucleotide reductase is required for ocular virulence.
The herpes simplex virus type 1 ICP6 gene is regulated by a 'leaky' early promoter.
The herpes simplex virus type 1 ribonucleotide reductase is a tight complex of the type alpha 2 beta 2 composed of 40K and 140K proteins, of which the latter shows multiple forms due to proteolysis.
The herpes simplex virus type 1 ribonucleotide reductase is required for acute retinal disease.
The herpes simplex virus type 1 temperature-sensitive mutant ts1222 has a single base pair deletion in the small subunit of ribonucleotide reductase.
The herpes simplex virus type 2 gene which encodes the large subunit of ribonucleotide reductase has unusual regulatory properties.
The hsv-2 la-1 oncoprotein is a member of a novel family of serine threonine receptor kinases.
The large subunit of herpes simplex virus type 1 ribonucleotide reductase: expression in Escherichia coli and purification.
The large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is associated with the virion tegument and has PK activity.
The novel protein kinase of the RR1 subunit of herpes simplex virus has autophosphorylation and transphosphorylation activity that differs in its ATP requirements for HSV-1 and HSV-2.
The pathogenicity of ribonucleotide reductase-null mutants of herpes simplex virus type 1 in mice.
The PK domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is required for immediate-early gene expression and virus growth.
The principal hydrogen donor for the herpes simplex virus type 1-encoded ribonucleotide reductase in infected cells is a cellular thioredoxin.
The protein kinase activity of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) fused to the extracellular domain of the epidermal growth factor receptor is ligand-inducible.
The R1 subunit of herpes simplex virus ribonucleotide reductase has chaperone-like activity similar to Hsp27.
The R1 subunit of herpes simplex virus ribonucleotide reductase is a good substrate for host cell protein kinases but is not itself a protein kinase.
The R1 subunit of herpes simplex virus ribonucleotide reductase protects cells against apoptosis at, or upstream of, caspase-8 activation.
The ribonucleotide reductase domain of the R1 subunit of herpes simplex virus type 2 ribonucleotide reductase is essential for R1 antiapoptotic function.
The ribonucleotide reductase induced by herpes simplex virus type 1 involves minimally a complex of two polypeptides (136K and 38K).
The ribonucleotide reductase inhibitor (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731): a potential topical therapy for herpes simplex virus infection.
The Ribonucleotide Reductase R1 Subunits of Herpes Simplex Virus 1 and 2 Protect Cells against Poly(I {middle dot} C)-Induced Apoptosis.
The ribonucleotide reductase R1 subunits of herpes simplex virus types 1 and 2 protect cells against TNF?- and FasL-induced apoptosis by interacting with caspase-8.
The role of herpes simplex virus ribonucleotide reductase small subunit carboxyl terminus in subunit interaction and formation of iron-tyrosyl center structure.
The RR1 gene of herpes simplex virus type 1 is uniquely trans activated by ICP0 during infection.
The small subunit of ribonucleotide reductase is encoded by one of the most abundant translationally regulated maternal RNAs in clam and sea urchin eggs.
The transmembrane domain of the large subunit of HSV-2 ribonucleotide reductase (ICP10) is required for protein kinase activity and transformation-related signaling pathways that result in ras activation.
The transmembrane helical segment but not the invariant lysine is required for the kinase activity of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10).
The UL5 gene of herpes simplex virus type 1: isolation of a lacZ insertion mutant and association of the UL5 gene product with other members of the helicase-primase complex.
The unique N terminus of herpes simplex virus type 1 ribonucleotide reductase large subunit is phosphorylated by casein kinase 2, which may have a homologue in Escherichia coli.
The unique N terminus of the herpes simplex virus type 1 large subunit is not required for ribonucleotide reductase activity.
The unique N-terminal domain of the large subunit of herpes simplex virus ribonucleotide reductase is preferentially sensitive to proteolysis.
Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy.
Topical treatment of infection with acyclovir-resistant mucocutaneous herpes simplex virus with the ribonucleotide reductase inhibitor 348U87 in combination with acyclovir.
Understanding the molecular mechanism of viral resistance to peptidomimetic inhibitors of ribonucleotide reductase.
Ureido-based peptidomimetic inhibitor of herpes simplex virus ribonucleotide reductase: an investigation of inhibitor bioactive conformation.
Vaccine potential of a herpes simplex virus type 2 mutant deleted in the PK domain of the large subunit of ribonucleotide reductase (ICP10).
[Characteristics and physical mapping of the gene of the herpes simplex virus that controls ribonucleotide reductase activity]
[The relationship between gene function and virulence in alpha-herpesviruses]
Herpes Zoster
Ribonucleotide reductase induced by varicella zoster virus. Characterization, and potentiation of acyclovir by its inhibition.
Studying protein complexes by the yeast two-hybrid system.
Synergistic topical therapy by acyclovir and A1110U for herpes simplex virus induced zosteriform rash in mice.
Hydatidiform Mole
[Changes in gene expression profiles of hydatidiform mole and choriocarcinoma as compared with trophoblast hyperplasia]
Hypersensitivity
Effect of deoxyribonucleosides on the hypersensitivity of human peripheral blood lymphocytes to UV-B and UV-C irradiation.
Herpes simplex virus ribonucleotide reductase mutants are hypersensitive to acyclovir.
Involvement of the PP2C-like phosphatase Ptc2p in the DNA checkpoint pathways of Saccharomyces cerevisiae.
Susceptibility of a herpes simplex virus ribonucleotide reductase null mutant to deoxyribonucleosides and antiviral nucleoside analogs.
Hypotension
[Does nitric oxide stress exist?]
Infections
A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells.
A new ribonucleotide reductase system after infection with phage T4.
A single point mutation in class III ribonucleotide reductase promoter renders Pseudomonas aeruginosa PAO1 inefficient for anaerobic growth and infection.
Analysis of cyclin-dependent kinase activity after herpes simplex virus type 2 infection.
Antibacterial activity of radical scavengers against class Ib ribonucleotide reductase from Bacillus anthracis.
Characterization of ribonucleotide reductase induction in BHK-21/C13 Syrian hamster cell line upon infection by herpes simplex virus (HSV).
Combination of inhibitors of lymphocyte activation (hydroxyurea, trimidox, and didox) and reverse transcriptase (didanosine) suppresses development of murine retrovirus-induced lymphoproliferative disease.
Correction for Dreux et al., Ribonucleotide Reductase Repressor NrdR as a Novel Regulator for Motility and Chemotaxis during Adherent-Invasive Escherichia coli Infection.
Differential effect of hydroxyurea on a ribonucleotide reductase system.
Direct activation of RIP3/MLKL-dependent necrosis by herpes simplex virus 1 (HSV-1) protein ICP6 triggers host antiviral defense.
Expression of the HSV-2 ribonucleotide reductase subunits in adenovirus vectors or stably transformed cells: restoration of enzymatic activity by reassociation of enzyme subunits in the absence of other HSV proteins.
Herpes simplex virus ribonucleotide reductase: expression in Escherichia coli and purification to homogeneity of a tyrosyl free radical-containing, enzymatically active form of the 38-kilodalton subunit.
Herpes simplex virus suppresses necroptosis in human cells.
Identification of a second functional glutaredoxin encoded by the bacteriophage T4 genome.
In vivo and in vitro comparison of the short-term hematopoietic toxicity between hydroxyurea and trimidox or didox, novel ribonucleotide reductase inhibitors with potential anti-HIV-1 activity.
In vivo function of the Murid Herpesvirus-4 ribonucleotide reductase small subunit.
Induction of a new ribonucleotide reductase after infection of mouse L cells with pseudorabies virus.
Induction of ribonucleotide reductase activity in cells infected with African swine fever virus.
Intracellular localisation of herpes simplex virus type 1 ribonucleotide reductase subunits during infection of cultured cells.
Intron-containing T4 bacteriophage gene sunY encodes an anaerobic ribonucleotide reductase.
Leishmania induces survival, proliferation and elevated cellular dNTP levels in human monocytes promoting acceleration of HIV co-infection.
Long-term HIV-1 infection induces an antiviral state in primary macrophages.
NrdH-redoxin mediates high enzyme activity in manganese-reconstituted ribonucleotide reductase from Bacillus anthracis.
Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus.
Potential for combined therapy with 348U87, a ribonucleotide reductase inhibitor, and acyclovir as treatment for acyclovir-resistant herpes simplex virus infection.
Ribonucleotide reductase from herpes simplex virus (types 1 and 2) infected and uninfected KB cells: properties of the partially purified enzymes.
Ribonucleotide reductase NrdR as a novel regulator for motility and chemotaxis during adherent-invasive Escherichia coli infection.
Ribonucleotide reductase of herpes simplex virus type 2 resembles that of herpes simplex virus type 1.
Ribonucleotide reductase of shrimp white spot syndrome virus (WSSV): expression and enzymatic activity in a baculovirus/insect cell system and WSSV-infected shrimp.
Roles of vaccinia virus ribonucleotide reductase and glutaredoxin in DNA precursor biosynthesis.
Shift in ribonucleotide reductase gene expression in Pseudomonas aeruginosa during infection.
Synergistic antiviral action of ribonucleotide reductase inhibitors and 3'-azido-3'-deoxythymidine on HIV type 1 infection in vitro.
T4 phage ribonucleotide reductase. Allosteric regulation in vivo by thymidine triphosphate.
The early expression of glycoprotein B from herpes simplex virus can be detected by antigen-specific CD8+ T cells.
The herpes simplex virus ribonucleotide reductase is required for ocular virulence.
The ribonucleotide reductase inhibitor (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731): a potential topical therapy for herpes simplex virus infection.
Topical treatment of infection with acyclovir-resistant mucocutaneous herpes simplex virus with the ribonucleotide reductase inhibitor 348U87 in combination with acyclovir.
Transcriptional analysis of the white spot syndrome virus major virion protein genes.
Treatment of human immunodeficiency virus infection with hydroxyurea: virologic and clinical evaluation.
Unusual regulation of expression of the herpes simplex virus DNA polymerase gene.
Vaccine potential of a herpes simplex virus type 2 mutant deleted in the PK domain of the large subunit of ribonucleotide reductase (ICP10).
Vaccinia virus-induced ribonucleotide reductase can be distinguished from host cell activity.
Kidney Neoplasms
A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma.
Leprosy
Ribonucleotide reductase as a drug target against drug resistance Mycobacterium leprae: A molecular docking study.
Leukemia
3-Chloro-N'-(2-hydroxybenzylidene) benzohydrazide: An LSD1-Selective Inhibitor and Iron-Chelating Agent for Anticancer Therapy.
A LC-MS/MS Method for the Analysis of Intracellular Nucleoside Triphosphate Levels.
A novel N-hydroxy-N'-aminoguanidine derivative inhibits ribonucleotide reductase activity: Effects in human HL-60 promyelocytic leukemia cells and synergism with arabinofuranosylcytosine (Ara-C).
A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study.
A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders.
Amidox, an inhibitor of ribonucleotide reductase, potentiates the action of Ara-C in HL-60 human promyelocytic leukemia cells.
Analysis of the ex vivo and in vivo antiretroviral activity of gemcitabine.
Analysis of the in vitro inhibition of murine and human tumor cell growth by pyrazole derivatives and a substituted azabicyclo [3.1.0] hexane-2,4-dione.
Anti-leukemia effect of resveratrol.
Antitumor effects of biologic reducing agents related to 3,4-dihydroxybenzylamine: dihydroxybenzaldehyde, dihydroxybenzaldoxime, and dihydroxybenzonitrile.
Avemar, a nontoxic fermented wheat germ extract, induces apoptosis and inhibits ribonucleotide reductase in human HL-60 promyelocytic leukemia cells.
Biochemical modulation of Ara-C effects by amidox, an inhibitor of ribonucleotide reductase in HL-60 promyelocytic human leukemia cells.
Biochemical modulation of aracytidine (Ara-C) effects by GTI-2040, a ribonucleotide reductase inhibitor, in K562 human leukemia cells.
Cell-cycle associated transcriptional regulation of ribonucleotide reductase in L1210 leukemia cells and drug-resistant variants.
Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia.
Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions.
Clinical toxic effects of 2,3-dihydro-1H-imidazo[1,2-b]pyrazole (IMPY) with relevant pharmacokinetic parameters.
Clofarabine Has Apoptotic Effect on T47D Breast Cancer Cell Line via P53R2 Gene Expression.
Differential effect of collaterally sensitive antimetabolites on P388 murine leukemia sensitive and resistant to adriamycin in vitro.
Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells.
Difluorodeoxyguanosine: cytotoxicity, metabolism, and actions on DNA synthesis in human leukemia cells.
Effect of FMdC on the cell cycle of some leukemia cell lines.
Effect of the solvent-dependent conformational system of hydroxyureas on predicted vs. observed log P.
Enhanced effects of adriamycin by combination with a new ribonucleotide reductase inhibitor, trimidox, in murine leukemia.
Gallic acid inhibits ribonucleotide reductase and cyclooxygenases in human HL-60 promyelocytic leukemia cells.
Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes.
In vivo growth of mouse leukemia L1210 cells with metabolic alterations in the subunits of ribonucleotide reductase.
Inhibition of ribonucleotide reductase, DNA synthesis, and L1210 leukemia by guanazole.
Iron deprivation decreases ribonucleotide reductase activity and DNA synthesis.
Leukocyte ribonucleotide reductase: studies in normal subjects and in subjects with leukemia or pernicious anemia.
Modulation of ara-CTP levels by fludarabine and hydroxyurea in leukemic cells.
N-hydroxy-N'-(3,4,5-trimethoxyphenyl)-3,4,5-trimethoxy-benzamidine, a novel resveratrol analog, inhibits ribonucleotide reductase in HL-60 human promyelocytic leukemia cells: Synergistic antitumor activity with arabinofuranosylcytosine.
Overexpression of the multidrug resistance genes mdr1, mdr3, and mrp in L1210 leukemia cells resistant to inhibitors of ribonucleotide reductase.
Overexpression of thioredoxin in Fanconi anemia fibroblasts prevents the cytotoxic and DNA damaging effect of mitomycin C and diepoxybutane.
Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia.
Potentiation of 2',3'-dideoxycytidine (ddC) by hydroxyurea and thymidine on the Moloney murine leukemia virus (MoMLV) early replicative steps.
Resveratrol, an ingredient of wine, acts synergistically with Ara-C and tiazofurin in HL-60 human promyelocytic leukemia cells.
Structure-function relationships for a new series of pyridine-2-carboxaldehyde thiosemicarbazones on ribonucleotide reductase activity and tumor cell growth in culture and in vivo.
The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase.
The ribonucleotide reductase inhibitor trimidox induces c-myc and apoptosis of human ovarian carcinoma cells.
Therapeutic response of leukemic mice treated with fluorinated pyrimidines and inhibitors of deoxyuridylate synthesis.
Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity.
Trimidox, an inhibitor of ribonucleotide reductase, induces apoptosis and activates caspases in HL-60 promyelocytic leukemia cells.
Trimidox, an inhibitor of ribonucleotide reductase, synergistically enhances the inhibition of colony formation by Ara-C in HL-60 human promyelocytic leukemia cells.
Leukemia L1210
Altered efflux properties of mouse leukemia L1210 cells resistant to 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
Altered sensitivity of deoxyadenosine-resistant mouse leukemia L1210 cells to various kinase inhibitors.
Blockage of cyclin cdk's, PKC and phosphoinositol 3-kinase pathways leads to augmentation of apoptosis in drug-resistant leukemia cells: evidence for interactive effects of flavopiridol, LY 294002, roscovitine,wortmannin and UCN-01.
Changes in messenger RNA levels for the subunits of ribonucleotide reductase during the cell cycle of leukemia L1210 cells.
Characterization of mouse leukemia L1210 cells resistant to the ribonucleotide reductase inhibitor 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
Differential turnover of the subunits of ribonucleotide reductase in synchronized leukemia L1210 cells.
Effects of 2',2'-difluorodeoxycytidine (Gemcitabine) on wild type and variant mouse leukemia L1210 cells.
Effects of biochemical modulation of drug combinations directed at the ribonucleotide reductase site on leukemia L1210 cell growth in culture.
Effects of N-hydroxy-N'-aminoguanidine isoquinoline in combination with other inhibitors of ribonucleotide reductase on L1210 cells.
Enhanced roscovitine-induced apoptosis is mediated by a caspase-3-like activity in deoxyadenosine-resistant mouse leukemia L1210 cells.
In vivo growth of mouse leukemia L1210 cells with metabolic alterations in the subunits of ribonucleotide reductase.
Increased sensitivity to sodium salicylate-induced apoptosis in drug-resistant leukemia L1210 cells.
Inhibition of ribonucleotide reductase and growth of human colon carcinoma HT-29 cells and mouse leukemia L1210 cells by N-hydroxy-N'-aminoguanidine derivatives.
Leukemia L1210 cell lines resistant to ribonucleotide reductase inhibitors.
Mouse leukemia L1210 cells selected for resistance to the ribonucleotide reductase inhibitor, 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone show altered response to DNA damaging agents.
Overexpression of protein disulfide isomerase-like protein in a mouse leukemia L1210 cell line selected for resistance to 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone, a ribonucleotide reductase inhibitor.
Phenotypic changes in mouse leukemia L1210 cells with alterations in the effector-binding subunit of ribonucleotide reductase.
Ribonucleotide reductase activity and growth of glutathione-depleted mouse leukemia L1210 cells in vitro.
Structural aspects of N-hydroxy-N'-aminoguanidine derivatives as inhibitors of L1210 cell growth and ribonucleotide reductase activity.
Substituted 2-acylpyridine-alpha-(N)-hetarylhydrazones as inhibitors of ribonucleotide reductase activity and L1210 cell growth.
[Biochemical mechanisms of resistance to a new antineoplastic drug CRC 680578 from the nitrosourea class]
Leukemia P388
[Changes in the activity of thymidine kinase, ribonucleotide reductase and DNA-polymerases during the development of leukemia P388 in mice]
Leukemia, Erythroblastic, Acute
Regulation of DNA synthesis by the higher-order chromatin structure.
Leukemia, Lymphocytic, Chronic, B-Cell
DNA repair initiation induces expression of ribonucleotide reductase in human chronic lymphocytic leukemia cells.
Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2'-deoxyadenosine (2-CdA) and Rituximab.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Knockdown of ribonucleotide reductase regulatory subunit M2 increases the drug sensitivity of chronic myeloid leukemia to imatinib?based therapy.
Leukemia, Myeloid
Development of resistance to hydroxyurea during treatment of human myelogenous leukemia K562 cells with alpha-difluoromethylornithine as a result of coamplification of genes for ornithine decarboxylase and ribonucleotide reductase R2 subunit.
Enhancement of hemoglobin and F-cell production by targeting growth inhibition and differentiation of K562 cells with ribonucleotide reductase inhibitors (didox and trimidox) in combination with streptozotocin.
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.
Leukemia, Myeloid, Acute
A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms.
CD33-Targeted Lipid Nanoparticles (aCD33LNs) for Therapeutic Delivery of GTI-2040 to Acute Myelogenous Leukemia.
Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase.
Phase I Study of GTI-2040, a Ribonucleotide Reductase Anti-Sense, with High Dose Cytarabine in Patients with Relapsed/Refractory Acute Myeloid Leukemia.
Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia.
RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia.
Leukemia, T-Cell
Overexpression of thioredoxin in Fanconi anemia fibroblasts prevents the cytotoxic and DNA damaging effect of mitomycin C and diepoxybutane.
Liver Neoplasms
[Apoptosis mechanism of taxol combined with resveratrol on human laryngeal carcinoma Hep-2 cells].
Liver Neoplasms, Experimental
Metabolism of 5-fluorouracil in sensitive and resistant Novikoff hepatoma cells.
Subcellular localization of ribonucleotide reductase in Novikoff hepatoma and regenerating rat liver.
Lung Neoplasms
(18)F-fluorodeoxyglucose Uptake with Expression of Excision Repair Cross-complementary Group 1 and Ribonucleotide Reductase Subunit M1 in Non-small Cell Lung Cancer.
An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines.
Association between epidermal growth factor receptor mutations and the expression of excision repair cross-complementing protein 1 and ribonucleotide reductase subunit M1 mRNA in patients with non-small cell lung cancer.
Broad overexpression of ribonucleotide reductase genes in mice specifically induces lung neoplasms.
Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy.
Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery.
cRGD Grafted siRNA Nano-constructs for Chemosensitization of Gemcitabine Hydrochloride in Lung Cancer Treatment.
DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer.
Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene.
ERCC1 and BRCA1 mRNA expressions are associated with clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.
ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis.
ERCC1 mRNA expression is associated with the clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I-III Non-Small Cell Lung Cancer.
Expression of RRM1 and its correlation with sensitivity to gemcitabine-based chemotherapy in advanced nasopharyngeal carcinoma.
Expression status of ribonucleotide reductase small subunits hRRM2/p53R2 as prognostic biomarkers in stage I and II non-small cell lung cancer.
Fusion of Quantitative Image and Genomic Biomarkers to Improve Prognosis Assessment of Early Stage Lung Cancer Patients.
Growth pattern analysis of murine lung neoplasms by advanced semi-automated quantification of micro-CT images.
In Situ Protein Expression of RRM1, ERCC1, and BRCA1 in Metastatic Breast Cancer Patients Treated with Gemcitabine-Based Chemotherapy.
In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy.
Lung cancer and the human gene for ribonucleotide reductase subunit M1 (RRM1).
Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancer.
Molecular predictors of response to chemotherapy in non-small cell lung cancer.
Molecular Targets of Gemcitabine Action: Rationale for Development of Novel Drugs and Drug Combinations.
Multiplex real-time PCR for RRM1, XRCC1, TUBB3 and TS mRNA for prediction of response of non-small cell lung cancer to chemoradiotherapy.
P53R2, p53 inducible ribonucleotide reductase gene, correlated with tumor progression of non-small cell lung cancer.
Polymorphisms in cancer-related pathway genes and lung cancer.
Polymorphisms of the ribonucleotide reductase M1 gene and sensitivity to platin-based chemotherapy in non-small cell lung cancer.
Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer.
Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells.
Predictors of biomarkers guiding targeted therapeutic strategies in locally advanced lung cancer.
Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy.
Prognostic significance of the mRNA expression of ERCC1, RRM1, TUBB3 and TYMS genes in patients with non-small cell lung cancer.
Prognostic value of ERCC1, RRM1, and TS proteins in patients with resected non-small cell lung cancer.
Prognostic value of ribonucleotide reductase subunit M1 (RRM1) in non-small cell lung cancer: A meta-analysis.
Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine.
RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer.
RRM1 expression and the clinicopathological characteristics of patients with non-small cell lung cancer treated with gemcitabine.
RRM1 gene expression in peripheral blood is predictive of shorter survival in Chinese patients with advanced non-small-cell lung cancer treated by gemcitabine and platinum.
Staurosporine increases toxicity of gemcitabine in non-small cell lung cancer cells: role of protein kinase C, deoxycytidine kinase and ribonucleotide reductase.
The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC).
The prognostic value of ERCC1 and RRM1 gene expression in completely resected non-small cell lung cancer: tumor recurrence and overall survival.
[Differential expressions of MDR-1, RRM-1, EGFR and ERCC-1 in primary tumors and metastatic lymph nodes of NSCLC patients].
[Expression and predictive role of excision repair cross complementation group 1, ribonucleotide reductase subunit M1, and ?-tubulin3 in postoperative patients with non-small cell lung cancer receiving adjuvant chemotherapy]
[Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines]
[Relationship between the efficacy of gemcitabine/cisplatin adjuvant chemotherapy and RRM1 protein expression in postoperative NSCLC patients].
Lymphadenitis
[SATB1 promotes the malignant of human non-Hodgkin lymphoma by activating the ribonucleotide reductase ?small subunit M2].
Lymphatic Metastasis
Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer.
Lymphoma
A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors.
Analysis of proliferating cell fraction determined by monoclonal antibody to M1-subunit ribonucleotide reductase and Ki-67 in relation to p53 protein expression in fine-needle aspirates from non-Hodgkin's lymphomas.
Demonstration of normal and mutant protein M1 subunits of deoxyGTP-resistant ribonucleotide reductase from mutant mouse lymphoma cells.
DeoxyATP-resistant ribonucleotide reductase of mutant mouse lymphoma cells. Evidence for heterozygosity for the protein M1 subunits.
Effect of cyclic AMP on the cell cycle regulation of ribonucleotide reductase M2 subunit messenger RNA concentrations in wild-type and mutant S49 T lymphoma cells.
Gallium compounds as antineoplastic agents.
HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma.
Intracellular deoxyribonucleotide pool imbalance and DNA damage in cells treated with hydroxyurea, an inhibitor of ribonucleotide reductase.
Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer.
Predictors of biomarkers guiding targeted therapeutic strategies in locally advanced lung cancer.
Ribonucleotide reductase gene expression during cyclic AMP-induced cell cycle arrest in T lymphocytes.
Ribonucleotide reductase in cultured mouse lymphoma cells. Cell cycle-dependent variation in the activity of subunit protein M2.
Ribonucleotide Reductase Inhibitor 3-AP Induces Oncogenic Virus Infected Cell Death and Represses Tumor Growth.
Ribonucleotide reductase represents a novel therapeutic target in primary effusion lymphoma.
Lymphoma, B-Cell
Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer.
Lymphoma, Large B-Cell, Diffuse
Increased level of ribonucleotide reductase in deoxyadenosine resistant adenosine deaminase deficient human histiocytic lymphoma cells.
Lymphoma, Mantle-Cell
HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma.
Lymphoma, Non-Hodgkin
Comparison of the expression of human equilibrative nucleotide transporter 1 (hENT1) and ribonucleotide reductase subunit M1 (RRM1) genes in seven non-Hodgkin lymphoma cell lines.
[SATB1 promotes the malignant of human non-Hodgkin lymphoma by activating the ribonucleotide reductase ?small subunit M2].
Lymphoma, Primary Effusion
Ribonucleotide reductase represents a novel therapeutic target in primary effusion lymphoma.
Lymphopenia
Resistance of an adenosine kinase-deficient human lymphoblastoid cell line to effects of deoxyadenosine on growth, S-adenosylhomocysteine hydrolase inactivation, and dATP accumulation.
Malaria
Antimalarial activities of polyhydroxyphenyl and hydroxamic acid derivatives.
Ribonucleotide reductase inhibitors with erythropoietin and iron sulfate against malaria.
Malaria, Vivax
[Determination of key interventions for the transition from control to elimination of malaria in China].
Marek Disease
Deletion of Marek's disease virus large subunit of ribonucleotide reductase impairs virus growth in vitro and in vivo.
Identification and in vitro characterization of a Marek's disease virus-encoded Ribonucleotide reductase.
Mastocytoma
Control of ribonucleotide reductase in heat- and cold-sensitive mammalian cell-cycle mutants.
Medulloblastoma
Synergistic cytotoxicity of the ribonucleotide reductase inhibitor didox (3,4-dihydroxy-benzohydroxamic acid) and the alkylating agent carmustine (BCNU) in 9L rat gliosarcoma cells and DAOY human medulloblastoma cells.
Melanoma
A novel human gene similar to the protein kinase (PK) coding domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) codes for a serine-threonine PK and is expressed in melanoma cells.
Bromodeoxyuridine mutagenesis, ribonucleotide reductase activity, and deoxyribonucleotide pools in hydroxyurea-resistant mutants.
Cytotoxic and biochemical effects of thymidine and 3-deazauridine on human tumor cells.
Focal adhesion kinase: a promising target for anticancer therapy.
Resistance to bromodeoxyuridine mutagenesis and toxicity in mammalian cells selected for resistance to hydroxyurea.
Ribonucleotide diphosphate reductase from human metastatic melanoma.
Ribonucleotide reductase and thymidylate synthase or exogenous deoxyribonucleosides reduce DNA damage and senescence caused by C-MYC depletion.
Ribonucleotide reductase in melanoma tissue. EPR detection in human amelanotic melanoma and quenching of the tyrosine radical by 4-hydroxyanisole.
siRNA Knockdown of Ribonucleotide Reductase Inhibits Melanoma Cell Line Proliferation Alone or Synergistically with Temozolomide.
Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma.
Melanoma, Amelanotic
Ribonucleotide reductase in melanoma tissue. EPR detection in human amelanotic melanoma and quenching of the tyrosine radical by 4-hydroxyanisole.
Melanoma, Experimental
Identification of 'non-proliferating' B16 melanoma cells using monoclonal antibody (AD203) against the M1 subunit of ribonucleotide reductase.
Meningioma
Hydroxyurea chemotherapy for unresectable or residual meningioma.
Hydroxyurea chemotherapy in the treatment of meningiomas.
Long-term follow-up result of hydroxyurea chemotherapy for recurrent meningiomas.
Nonsurgical treatment options in the management of intracranial meningiomas.
Mesothelioma
Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery.
Mitochondrial Diseases
Kearns-Sayre syndrome caused by defective R1/p53R2 assembly.
Mouth Neoplasms
Ribonucleotide reductase small subunit p53R2 promotes oral cancer invasion via the E-cadherin/beta-catenin pathway.
Multiple Myeloma
An in-silico approach to predict and exploit synthetic lethality in cancer metabolism.
Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells.
Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma.
Murine Acquired Immunodeficiency Syndrome
Analysis of the ex vivo and in vivo antiretroviral activity of gemcitabine.
Effective use of ribonucleotide reductase inhibitors (Didox and Trimidox) alone or in combination with didanosine (ddI) to suppress disease progression and increase survival in murine acquired immunodeficiency syndrome (MAIDS).
Muscle Hypotonia
Mitochondrial DNA depletion syndrome due to mutations in the RRM2B gene.
Myeloproliferative Disorders
A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders.
ATR activation necessary but not sufficient for p53 induction and apoptosis in hydroxyurea-hypersensitive myeloid leukemia cells.
Metastatic squamous cell carcinoma of the skin in chronic myeloid leukaemia: complication of hydroxyurea therapy.
Myoma
[Active form of ribonucleotide reductase and level of free iron in human uterine myoma]
[The ribonucleotide reductase content in a uterine myoma]
Nasopharyngeal Carcinoma
Antibodies against the large subunit of the EBV-encoded ribonucleotide reductase in patients with nasopharyngeal carcinoma.
Distribution of epstein-barr virus antigenic sites on the carboxyl terminal end of ribonucleotide reductase against nasopharyngeal carcinoma serum antibodies using an immunoabsorption method.
Enzyme-linked immunosorbent assay (ELISA) for IgA and IgG antibodies to Epstein-Barr-virus ribonucleotide reductase in patients with nasopharyngeal carcinoma.
p53R2 as a novel prognostic biomarker in nasopharyngeal carcinoma.
Ribonucleotide reductase inhibitors enhance cidofovir-induced apoptosis in EBV-positive nasopharyngeal carcinoma xenografts.
Nasopharyngeal Neoplasms
Overexpression of the R2 subunit of ribonucleotide reductase in human nasopharyngeal cancer cells reduces radiosensitivity.
Neoplasm Metastasis
A small molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance.
An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma.
Antitumor and radiosensitizing effects of (E)-2'-deoxy-2'-(fluoromethylene) cytidine, a novel inhibitor of ribonucleoside diphosphate reductase, on human colon carcinoma xenografts in nude mice.
Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus.
Expanding horizons in iron chelation and the treatment of cancer: Role of iron in the regulation of ER stress and the epithelial-mesenchymal transition.
Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro.
Lack of correlation between deoxyribonucleotide pool sizes, spontaneous mutation rates and malignant potential in Chinese hamster ovary cells.
Molecular genetic analysis of primary lung cancer and cancer metastatic to the lung.
Ribonucleotide reductase large subunit M1 plays a different role in the invasion and metastasis of papillary thyroid carcinoma and undifferentiated thyroid carcinoma.
Ribonucleotide reductase small subunit M2B prognoses better survival in colorectal cancer.
Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer.
RNA interference targeting the R2 subunit of ribonucleotide reductase inhibits growth of tumor cells in vitro and in vivo.
The renaissance of polypharmacology in the development of anti-cancer therapeutics: Inhibition of the "Triad of Death" in cancer by Di-2-pyridylketone thiosemicarbazones.
The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer.
Transforming growth factor beta and fibroblast growth factor as promoters of tumor progression to malignancy.
[Study of DNA microarray chip of associated genes of hydatidiform mole]
Neoplasms
5-aza-2',2'-Difluroro Deoxycytidine (NUC013): A Novel Nucleoside DNA Methyl Transferase Inhibitor and Ribonucleotide Reductase Inhibitor for the Treatment of Cancer.
A cis-trans interaction at the 3'-untranslated region of ribonucleotide reductase mRNA is regulated by TGF-beta 1, TGF-beta 2, and TGF-beta 3.
A comparison of ribonucleotide reductase activities in normal human fibroblast strains with their transformed counterparts.
A dityrosyl-diiron radical cofactor center is essential for human ribonucleotide reductases.
A Ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase.
A microfluidic method to synthesize transferrin-lipid nanoparticles loaded with siRNA LOR-1284 for therapy of acute myeloid leukemia.
A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors.
A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression.
A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.
A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer.
A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms.
A prospective study of biomarker-guided chemotherapy in patients with non-small cell lung cancer.
A restriction cleavage and transfection system for introducing foreign DNA sequences into the genome of a herpesvirus.
A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage.
A RIBONUCLEOTIDE REDUCTASE INHIBITOR REVERSES BURN INDUCED INFLAMMATORY DEFECTS.
A ribonucleotide reductase inhibitor, MDL 101,731, induces apoptosis and elevates TRPM-2 mRNA levels in human prostate tumor xenografts.
A simple and sensitive ribonucleotide reductase assay.
A small molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance.
Acetylation regulates ribonucleotide reductase activity and cancer cell growth.
Activity of the cytosolic isozyme of thymidine kinase in human primary lung tumors with reference to malignancy.
Advanced squamous lung carcinoma in a patient experiencing long-term survival following repeated responses to gemcitabine and cisplatin chemotherapy: A case report.
Alterations in the activity and regulation of mammalian ribonucleotide reductase by chlorambucil, a DNA damaging agent.
Altered regulation of message stability and tumor promoter-responsive cis-trans interactions of ribonucleotide reductase R1 and R2 messenger RNAs in hydroxyurea-resistant cells.
An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy.
Analysis of candidate gene co-amplification with MYCN in neuroblastoma.
Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment.
Analysis of the ex vivo and in vivo antiretroviral activity of gemcitabine.
Association of Novel Gene Polymorphisms RRM1 -756T>C and -269 C>A With Breast Cancer.
Association of the Genetic Polymorphisms RRM1 -756T>C and -269C>A With Cervical Neoplasia.
Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase.
Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector.
Cell cycle perturbation induced by gemcitabine in human tumor cells in cell culture, xenografts and bladder cancer patients: implications for clinical trial designs combining gemcitabine with a Chk1 inhibitor.
Cellular signaling pathways affect the function of ribonucleotide reductase mRNA binding proteins: mRNA stabilization, drug resistance, and malignancy (Review).
Chelators controlling metal metabolism and toxicity pathways: applications in cancer prevention, diagnosis and treatment.
Clinical evaluation of postoperative chemotherapy based on genetic testing in patients with stage IIIA non-small cell lung cancer.
Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?
Cytotoxic and biochemical effects of 3,3',4,4',5,5'-hexahydroxystilbene, a novel resveratrol analog in HL-60 human promyelocytic leukemia cells.
Cytotoxic Evaluation of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, 3-AP, in Peripheral Blood Lymphocytes of Patients with Refractory Solid Tumors using Electron Paramagnetic Resonance.
Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation.
Defining a novel cis-element in the 3'-untranslated region of mammalian ribonucleotide reductase component R2 mRNA. cis-trans-interactions and message stability.
Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints.
Deoxynucleoside Salvage Facilitates DNA Repair During Ribonucleotide Reductase Blockade in Human Cervical Cancers.
Development of new deoxycytidine kinase inhibitors and noninvasive in vivo evaluation using positron emission tomography.
Dibutyltin(IV) complexes containing arylazobenzoate ligands: chemistry, in vitro cytotoxic effects on human tumor cell lines and mode of interaction with some enzymes.
Didox (3,4-dihydroxybenzohydroxamic acid) suppresses IgE-mediated mast cell activation through attenuation of NF?B and AP-1 transcription.
Differential effect of collaterally sensitive antimetabolites on P388 murine leukemia sensitive and resistant to adriamycin in vitro.
Differential expression of ERCC-1 in the primary tumors and metastatic lymph nodes of patients with non-small cell lung cancer adenocarcinoma.
Digalloylresveratrol, a new phenolic acid derivative induces apoptosis and cell cycle arrest in human HT-29 colon cancer cells.
Digalloylresveratrol, a novel resveratrol analog inhibits the growth of human pancreatic cancer cells.
DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer.
Downregulation of ribonucleotide reductase subunits M2 induces apoptosis and G1 arrest of cervical cancer cells.
Drug metabolism and homologous recombination repair in radiosensitization with gemcitabine.
E2F1 promote the aggressiveness of human colorectal cancer by activating the ribonucleotide reductase small subunit M2.
Effect of FMdC on the cell cycle of some leukemia cell lines.
Effects of biochemical modulation of drug combinations directed at the ribonucleotide reductase site on leukemia L1210 cell growth in culture.
Effects of N-hydroxy-N'-aminoguanidine derivatives on ribonucleotide reductase activity, nucleic acid synthesis, clonogenicity, and cell cycle of L1210 cells.
Effects of the ferrous chelate of 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone (MAIQ-1) on the kinetics of reduction of CDP by ribonucleotide reductase of the Novikoff tumor.
Elevated ribonucleotide reductase levels associate with suppressed radiochemotherapy response in human cervical cancers.
Enhanced effects of adriamycin by combination with a new ribonucleotide reductase inhibitor, trimidox, in murine leukemia.
Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models.
Enhancement of DNA ligase I level by gemcitabine in human cancer cells.
Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus.
ERCC1 and RRM1: Ready for Prime Time?
ESR studies on reactivity of protein-derived tyrosyl radicals formed by prostaglandin H synthase and ribonucleotide reductase.
Evaluating the Therapeutic Potential of a Non-Natural Nucleotide that Inhibits Human Ribonucleotide Reductase.
Evaluation of combinations of drugs that inhibit Ehrlich tumor cell ribonucleotide reductase.
Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors.
Evaluation of pseudorabies virus as a gene transfer vector and an oncolytic agent for human tumor cells.
Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.
Expanding horizons in iron chelation and the treatment of cancer: Role of iron in the regulation of ER stress and the epithelial-mesenchymal transition.
Expression of Bcl-2 family member Bid in normal and malignant tissues.
Expression of ribonucleotide reductase after ionizing radiation in human cervical carcinoma cells.
Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro.
Expression status of ribonucleotide reductase small subunits hRRM2/p53R2 as prognostic biomarkers in stage I and II non-small cell lung cancer.
Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer.
Focal adhesion kinase: a promising target for anticancer therapy.
Fusion of Quantitative Image and Genomic Biomarkers to Improve Prognosis Assessment of Early Stage Lung Cancer Patients.
Gallium and other main group metal compounds as antitumor agents.
Gallium in cancer treatment.
Gallium Maltolate Disrupts Tumor Iron Metabolism and Retards the Growth of Glioblastoma by Inhibiting Mitochondrial Function and Ribonucleotide Reductase.
Gallium nitrate for the treatment of non-Hodgkin's lymphoma.
Gemcitabine-Based Chemotherapy in Adrenocortical Carcinoma: A Multicenter Study of Efficacy and Predictive Factors.
Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.
GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine.
Growth pattern analysis of murine lung neoplasms by advanced semi-automated quantification of micro-CT images.
GTI-2040 displays cooperative anti-tumor activity when combined with interferon alpha against human renal carcinoma xenografts.
GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors.
GTI-2040. Lorus Therapeutics.
GTI-2501, an antisense agent targeting R1, the large subunit of human ribonucleotide reductase, shows potent anti-tumor activity against a variety of tumors.
GTI-2501. Lorus Therapeutics.
Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis.
Hydroxyurea-induced leg ulcers: is macroerythrocytosis a pathogenic factor?
Identification of F-box/LLR-repeated protein 17 as potential useful biomarker for breast cancer therapy.
Identification of Non-nucleoside Human Ribonucleotide Reductase Modulators.
Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles.
Impaired function of p53R2 in Rrm2b-null mice causes severe renal failure through attenuation of dNTP pools.
In vivo growth of mouse leukemia L1210 cells with metabolic alterations in the subunits of ribonucleotide reductase.
In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant.
Inactivation of ribonucleotide reductase by nitric oxide.
Inactivation of ribonucleotide reductase in tumour cells and inhibition of tumour cell growth by p-alkoxyphenols.
Individualized Chemotherapy in Advanced NSCLC Patients Based on mRNA Levels of BRCA1 and RRM1.
Inhibition of human cancer cell growth by inducible expression of human ribonucleotide reductase antisense cDNA.
Inhibition of leukemic HL60 cell growth by transferrin-gallium: effects on ribonucleotide reductase and demonstration of drug synergy with hydroxyurea.
Inhibition of Poly(ADP-Ribose) Polymerase Enhances Radiochemosensitivity in Cancers Proficient in DNA Double-Strand Break Repair.
Inhibition of ribonucleotide reductase activity and nucleic acid synthesis in tumor cells by the dialdehyde derivatives of inosine (NSC 118994) and inosinic acid.
Inhibition of ribonucleotide reductase and growth of human colon carcinoma HT-29 cells and mouse leukemia L1210 cells by N-hydroxy-N'-aminoguanidine derivatives.
Inhibition of ribonucleotide reductase by caracemide.
Inhibition of ribonucleotide reductase from Ehrlich tumor cells by RNA.
Inhibition of tumor cell ribonucleotide reductase by macrophage-derived nitric oxide.
Interaction of gallium nitrate with other inhibitors of ribonucleotide reductase: effects on the proliferation of human leukemic cells.
Investigation of co-amplification of the candidate genes ornithine decarboxylase, ribonucleotide reductase, syndecan-1 and a DEAD box gene, DDX1, with N-myc in neuroblastoma. United Kingdom Children's Cancer Study Group.
Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase.
Iron and haem complexation studies of 2,3-dihydro-1H-imidazo(1,2-b)pyrazole (IMPY, NSC 51143), a tumour cell ribonucleotide reductase inhibitor.
Iron binding capacity of didox (3,4 dihydroxybenzohydroxamic acid) and amidox (3,4 dihydroxybenzamidoxime) two inhibitors of the enzyme ribonucleotide reductase.
Iron binding capacity of didox (3,4-dihydroxybenzohydroxamic acid) and amidox (3,4-dihydroxybenzamidoxime) new inhibitors of the enzyme ribonucleotide reductase.
Iron binding capacity of trimidox (3,4,5-trihydroxybenzamidoxime), a new inhibitor of the enzyme ribonucleotide reductase.
Iron-targeting antitumor activity of gallium compounds and novel insights into Triapine®-metal complexes.
Irreversible inhibition of ribonucleotide reductase from Ehrlich tumor cells by a modulator analog.
Is ribonucleotide reductase in Ehrlich ascites mammary tumour cells the target of a growth inhibitor purified from bovine mammary gland?
Lack of correlation between deoxyribonucleotide pool sizes, spontaneous mutation rates and malignant potential in Chinese hamster ovary cells.
Lessons Learned from Gemcitabine: Impact of Therapeutic Carrier Systems and Gemcitabine's Drug Conjugates on Cancer Therapy.
Let-7 Sensitizes KRAS Mutant Tumor Cells to Chemotherapy.
Long-term survival in a rodent brain tumor model by bradykinin-enhanced intra-arterial delivery of a therapeutic herpes simplex virus vector.
Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene.
Mammalian ribonucleotide reductase R1 mRNA stability under normal and phorbol ester stimulating conditions: involvement of a cis-trans interaction at the 3' untranslated region.
Mechanism for induction of hydroxyurea resistance and loss of latent EBV genome in hydroxyurea-treated Burkitt's lymphoma cell line Raji.
Mechanism of action of key enzymes associated with cancer propagation and their inhibition by various chemotherapeutic agents.
Metastasis-suppressing potential of ribonucleotide reductase small subunit p53R2 in human cancer cells.
miR-211 regulates the expression of RRM2 in tumoral metastasis and recurrence in colorectal cancer patients with a k-ras gene mutation.
Mode of inhibition of tumor cell ribonucleotide reductase by 2,3-dihydro-1H-pyrazolo[2,3-a]imidazole (NSC 51143).
Modulating radiation resistance by inhibiting ribonucleotide reductase in cancers with virally or mutationally silenced p53 protein.
Molecular analysis-based treatment strategies for the management of non-small cell lung cancer.
Molecular basis of the interaction of novel tributyltin(IV) 2/4-[(E)-2-(aryl)-1-diazenyl]benzoates endowed with an improved cytotoxic profile: synthesis, structure, biological efficacy and QSAR studies.
Monoclonal antibody to HSV2 protein as an immunodiagnostic marker in cervical cancer.
Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.
Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats.
Nano-Diamino-Tetrac (NDAT) Enhances Resveratrol-Induced Antiproliferation by Action on the RRM2 Pathway in Colorectal Cancers.
Neuroprotective activity of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (PAN-811), a cancer therapeutic agent.
New Water-Soluble Copper(II) Complexes with Morpholine-Thiosemicarbazone Hybrids: Insights into the Anticancer and Antibacterial Mode of Action.
Novel biological radiochemotherapy approaches in locally advanced-stage cervical cancer management.
Novel Insights into Gallium's Mechanism of Therapeutic Action: A DFT/PCM Study of the Interaction between Ga3+ and Ribonucleotide Reductase Substrates.
Novel Triapine Derivative Induces Copper-Dependent Cell Death in Hematopoietic Cancers.
Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line.
Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis.
Overexpression of RRM2 in gastric cancer cell promotes their invasiveness via AKT/NF-?B signaling pathway.
Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential.
P21-activated kinase 1 (Pak1) signaling influences therapeutic outcome in pancreatic cancer.
p53R2 inhibits the proliferation of human cancer cells in association with cell-cycle arrest.
P53R2, p53 inducible ribonucleotide reductase gene, correlated with tumor progression of non-small cell lung cancer.
PAN-811 Inhibits Oxidative Stress-Induced Cell Death of Human Alzheimer's Disease-Derived and Age-Matched Olfactory Neuroepithelial Cells Via Suppression of Intracellular Reactive Oxygen Species.
Paracetamol inhibits replicative DNA synthesis and induces sister chromatid exchange and chromosomal aberrations by inhibition of ribonucleotide reductase.
Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion.
Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies.
Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study.
Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer.
Phorbol ester modulation of a novel cytoplasmic protein binding activity at the 3'-untranslated region of mammalian ribonucleotide reductase R2 mRNA and role in message stability.
Physical interaction between human ribonucleotide reductase large subunit and thioredoxin increases colorectal cancer malignancy.
Plk1 inhibition enhances the efficacy of gemcitabine in human pancreatic cancer.
Potent competitive inhibition of human ribonucleotide reductase by a nonnucleoside small molecule.
Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo.
Potent subunit-specific effects on cell growth and drug sensitivity from optimised siRNA-mediated silencing of ribonucleotide reductase.
Potentiation of hydroxyurea cytotoxicity by iron-chelating agent in murine tumor models in vitro.
Preclinical characteristics of gemcitabine.
Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma.
Production of a monoclonal antibody against the hRRM2 subunit of ribonucleotide reductase and immunohistochemistry study of human cancer tissues.
Prognostic and therapeutic significance of ribonucleotide reductase small subunit M2 in estrogen-negative breast cancers.
Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer.
Properties of N-hydroxy-N'-aminoguanidine derivatives as inhibitors of mammalian ribonucleotide reductase.
Properties of ribonucleotide reductase from Ehrlich tumor cells; multiple nucleoside diphosphate activities and reconstitution of activity from components.
Quenching of the tyrosyl free radical of ribonucleotide reductase by nitric oxide. Relationship to cytostasis induced in tumor cells by cytotoxic macrophages.
Quenching of tyrosine radicals of M2 subunit from ribonucleotide reductase in tumor cells by different antitumor agents: an EPR study.
Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers.
Radiopharmaceuticals for Persistent or Recurrent Uterine Cervix Cancer.
Reconstitution of the ribonucleotide reductase enzyme from Ehrlich tumor cells.
Regulation and drug resistance mechanisms of mammalian ribonucleotide reductase, and the significance to DNA synthesis.
Regulation of mammalian ribonucleotide reductase by the tumor promoters and protein phosphatase inhibitors okadaic acid and calyculin A.
Response of human colon and prostate tumor xenografts to (E)-2'-deoxy-2'-(fluoromethylene) cytidine, an inhibitor of ribonucleotide reductase.
Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad?
Resveratrol, a remarkable inhibitor of ribonucleotide reductase.
Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase: A novel therapeutic strategy in pancreatic cancer.
Ribonucleotide reductase activity during the growth of Ehrlich ascites tumor.
Ribonucleotide reductase activity in cell-free extracts of Yaba poxvirus tumor and normal monkey tissues.
Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies.
Ribonucleotide reductase and cell proliferation. I. Variations of ribonucleotide reductase activity with tumor growth rate in a series of rat hepatomas.
Ribonucleotide reductase and DNA synthesis in Ehrlich ascites tumor cells.
Ribonucleotide reductase as a chemotherapeutic target.
Ribonucleotide reductase as one important target of [Tris(1,10-phenanthroline)lanthanum(III)] trithiocyanate (KP772).
Ribonucleotide reductase in ascites tumour cells detected by electron paramagnetic resonance spectroscopy.
Ribonucleotide reductase in melanoma tissue. EPR detection in human amelanotic melanoma and quenching of the tyrosine radical by 4-hydroxyanisole.
Ribonucleotide Reductase Inhibition Enhances Chemoradiosensitivity of Human Cervical Cancers.
Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers.
Ribonucleotide Reductase Inhibitor 3-AP Induces Oncogenic Virus Infected Cell Death and Represses Tumor Growth.
Ribonucleotide reductase inhibitors: a new look at an old target for radiosensitization.
Ribonucleotide reductase inhibitors: new strategies for cancer chemotherapy.
Ribonucleotide reductase large subunit M1 plays a different role in the invasion and metastasis of papillary thyroid carcinoma and undifferentiated thyroid carcinoma.
Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines.
Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma.
Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential.
Ribonucleotide reductase R2 gene expression and changes in drug sensitivity and genome stability.
Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patients.
Ribonucleotide reductase subunit one as gene therapy target: commentary re: M-Y. Cao et al., Adenovirus-mediated ribonucleotide reductase R1 gene therapy of human colon adenocarcinoma. Clin. Cancer Res., 9: 4304-4308, 2003.
Ribonucleotide reductase subunit p53R2 regulates mitochondria homeostasis and function in KB and PC-3 cancer cells.
Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine.
Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer.
Ribonucleotide reductase: a critical enzyme for cancer chemotherapy and antiviral agents.
Ribonucleotide reductase M2 subunit expression and prognostic value in nasopharyngeal carcinoma.
RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine.
RNA interference targeting the R2 subunit of ribonucleotide reductase inhibits growth of tumor cells in vitro and in vivo.
Role of antimetabolites of purine and pyrimidine nucleotide metabolism in tumor cell differentiation.
Role of ribonucleotide reductase in regulation of cell cycle progression during and after exposure to moderate hypoxia.
RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer.
RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients.
RRM2 induces NF-kappaB-dependent MMP-9 activation and enhances cellular invasiveness.
RRM2 regulates Bcl-2 in head and neck and lung cancers: a potential target for cancer therapy.
Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7.
Sequencing cyclic peptide inhibitors of mammalian ribonucleotide reductase by electrospray ionization mass spectrometry.
Silencing of ribonucleotide reductase subunit M1 potentiates the antitumor activity of gemcitabine in resistant cancer cells.
siRNA Knockdown of Ribonucleotide Reductase Inhibits Melanoma Cell Line Proliferation Alone or Synergistically with Temozolomide.
Specific inhibitors directed at the individual components of ribonucleotide reductase as an approach to combination chemotherapy.
Stability and reactivation of tyrosine radicals from ribonucleotide reductase in tumor cells studied by ESR.
Structure-based optimization of peptide inhibitors of mammalian ribonucleotide reductase.
Structure-function relationships for a new series of pyridine-2-carboxaldehyde thiosemicarbazones on ribonucleotide reductase activity and tumor cell growth in culture and in vivo.
Structure-guided design of anti-cancer ribonucleotide reductase inhibitors.
Structure-Guided Synthesis and Mechanistic Studies Reveal Sweetspots on Naphthyl Salicyl Hydrazone Scaffold as Non-Nucleosidic Competitive, Reversible Inhibitors of Human Ribonucleotide Reductase.
Studies of N-hydroxy-N'-aminoguanidine derivatives by nitrogen-15 nuclear magnetic resonance spectroscopy and as ribonucleotide reductase inhibitors.
Studies on mammalian ribonucleotide reductase inhibition by pyridoxal phosphate and the dialdehyde derivatives of adenosine, adenosine 5'-monophosphate, and adenosine 5'-triphosphate.
Substituted 2-acylpyridine-alpha-(N)-hetarylhydrazones as inhibitors of ribonucleotide reductase activity and L1210 cell growth.
Success and failure of dendritic cell (DC) anticancer activity may be modulated by nitric oxide synthetase (NOS) gene expression: a hypothesis.
Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase.
Suppression of malignancy by the 3' untranslated regions of ribonucleotide reductase R1 and R2 messenger RNAs.
Synergistic growth inhibitory and differentiating effects of trimidox and tiazofurin in human promyelocytic leukemia HL-60 cells.
Synthesis and biological evaluation of O-alkylated tropolones and related alpha-ketohydroxy derivatives as ribonucleotide reductase inhibitors.
Synthesis and evaluation of new salicylaldehyde-2-picolinylhydrazone Schiff base compounds of Ru(II), Rh(III) and Ir(III) as in vitro antitumor, antibacterial and fluorescence imaging agents.
Synthesis and evaluation of novel polyaminocarboxylate-based antitumor agents.
Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles.
Synthesis of novel D- and L-3'-deoxy-3'-C-hydroxymethyl nucleoside with exocyclic methylene as potential ribonucleotide reductase inhibitor.
Synthesis, Physicochemical Studies, Molecular Dynamics Simulations, and Metal-Ion-Dependent Antiproliferative and Antiangiogenic Properties of Cone ICL670-Substituted Calix[4]arenes.
Tailor-made chemotherapy for non-small cell lung cancer patients.
Targeting ribonucleotide reductase for cancer therapy.
Targeting ribonucleotide reductase M2 subunit by small interfering RNA exerts anti-oncogenic effects in gastric adenocarcinoma.
Targeting the Large Subunit of Human Ribonucleotide Reductase for Cancer Chemotherapy.
Tezacitabine Hoechst Marion Roussel.
The 11p15.5 ribonucleotide reductase M1 subunit locus is not imprinted in Wilms' tumour and hepatoblastoma.
The antiproliferative activity of resveratrol results in apoptosis in MCF-7 but not in MDA-MB-231 human breast cancer cells: cell-specific alteration of the cell cycle.
The Antitumor Didox Acts as an Iron Chelator in Hepatocellular Carcinoma Cells.
The combination of ascorbate and menadione causes cancer cell death by oxidative stress and replicative stress.
The effect of dinitrosyl iron complexes with glutathione and S-nitrosoglutathione on the development of experimental endometriosis in rats: a comparative studies.
The effects of lithium in reversing hydroxyurea induced suppression of hematopoietic progenitor cells in vitro using retroviral infected long-term marrow cultures.
The enzyme ribonucleotide reductase: target for antitumor and anti-HIV therapy.
The expression of ribonucleotide reductase m2 in the carcinogenesis of uterine cervix and its relationship with clinicopathological characteristics and prognosis of cancer patients.
The genome of canarypox virus.
The in vivo toxicity of hydroxyurea depends on its direct target catalase.
The molecular weight of Ehrlich tumor cell ribonucleotide reductase and its subunits: effector-induced changes.
The Novel Ribonucleotide Reductase Inhibitor COH29 Inhibits DNA Repair In Vitro.
The potential role of pharmacogenomic and genomic in the adjuvant treatment of early stage non small cell lung cancer.
The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments.
The renaissance of polypharmacology in the development of anti-cancer therapeutics: Inhibition of the "Triad of Death" in cancer by Di-2-pyridylketone thiosemicarbazones.
The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer.
The Ribonucleotide Reductase R1 Subunits of Herpes Simplex Virus 1 and 2 Protect Cells against Poly(I {middle dot} C)-Induced Apoptosis.
The ribonucleotide reductase R1 subunits of herpes simplex virus types 1 and 2 protect cells against TNF?- and FasL-induced apoptosis by interacting with caspase-8.
The roles of p53R2 in cancer progression based on the new function of mutant p53 and cytoplasmic p21.
Thiosemicarbazone derivatives, thiazolyl hydrazones, effectively inhibit leukemic tumor cell growth: Down-regulation of ribonucleotide reductase activity and synergism with arabinofuranosylcytosine.
Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo.
Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.
Transcriptional responses to ionizing radiation reveal that p53R2 protects against radiation-induced mutagenesis in human lymphoblastoid cells.
Transforming growth factor beta and fibroblast growth factor as promoters of tumor progression to malignancy.
Transient elevation of ribonucleotide reductase activity, M2 mRNA and M2 protein in BALB/c 3T3 fibroblasts in the presence of 12-O-tetradecanoylphorbol-13-acetate.
Triapine Radiochemotherapy in Advanced Stage Cervical Cancer.
Trimidox, an inhibitor of ribonucleotide reductase, synergistically enhances the inhibition of colony formation by Ara-C in HL-60 human promyelocytic leukemia cells.
Tumor suppressor FOXO3 regulates ribonucleotide reductase subunit RRM2B and impacts on survival of cancer patients.
Understanding Ribonucleotide Reductase Inactivation by Gemcitabine.
Upregulation of enzymes metabolizing 5-fluorouracil in colorectal cancer.
Utility of hydroxyurea in mast cell activation syndrome.
Valproic acid sensitizes breast cancer cells to hydroxyurea through inhibiting RPA2 hyperphosphorylation-mediated DNA repair pathway.
Variation in the expression levels of predictive chemotherapy biomarkers in histological subtypes of lung adenocarcinoma: an immunohistochemical study of tissue samples.
Weighing tumor biology in treatment decisions for patients with non-small cell lung cancer.
[Apoptosis mechanism of taxol combined with resveratrol on human laryngeal carcinoma Hep-2 cells].
[Changes in ribonucleotide reductase activity in mouse leukemic cells and spleen during in vivo tumor growth and hydroxyurea administration]
[Changes in the replication apparatus and phosphorus-containing metabolite pool in experimental tumors in animals during development]
[Differential expressions of MDR-1, RRM-1, EGFR and ERCC-1 in primary tumors and metastatic lymph nodes of NSCLC patients].
[Dinitrosyl iron complexes with glutathione recover rats with experimental endometriosis].
[Markers of the metabolic changes arising as a result of ionizing radiation exposure]
[Non-clinical studies of gemcitabine--the mode of action and antitumor activities]
[Paramagnetic form of ribonucleotide reductase in human tissues]
[Relations between RRM1 protein expression levels and effects of gemcitabine and cisplatin chemotherapy in advanced non-small cell lung cancer patients].
[Ribonucleotide reductase from a mammalian rat tumor (Zajdela's hepatoma): stereospecificity of the reduction]
[Studies on the mechanism of cytotoxicity of 5-fluorouracil--through impairment of metabolism]
[Studies on the thymidine-triphosphate synthesis in malignant tumors. I. Effects of thymidine on deoxyribonucleoside triphosphate pools and deoxyribonucleic acid synthesis (author's trans)]
[Studies on the thymidine-triphosphate synthesis in malignant tumors. II. Effect of hyperthermia, Vitamin K and Cytotoxic agents (author's transl)]
[Study of DNA microarray chip of associated genes of hydatidiform mole]
[The EPR spectra of the ribonucleotide reductase in the tumorous tissues and organs of tumor-bearing animals]
Neural Tube Defects
Ribonucleotide reductase subunit R1: a gene conferring sensitivity to valproic acid-induced neural tube defects in mice.
Neurilemmoma
Treatment of Schwannomas with an Oncolytic Recombinant Herpes Simplex Virus in Murine Models of Neurofibromatosis Type 2.
Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2.
Neuroblastoma
3-Chloro-N'-(2-hydroxybenzylidene) benzohydrazide: An LSD1-Selective Inhibitor and Iron-Chelating Agent for Anticancer Therapy.
Analysis of candidate gene co-amplification with MYCN in neuroblastoma.
Effect of adenosine analogues on protein carboxylmethyltransferase, S-adenosylhomocysteine hydrolase, and ribonucleotide reductase activity in murine neuroblastoma cells.
Investigation of co-amplification of the candidate genes ornithine decarboxylase, ribonucleotide reductase, syndecan-1 and a DEAD box gene, DDX1, with N-myc in neuroblastoma. United Kingdom Children's Cancer Study Group.
Neurofibrosarcoma
Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants.
Neutropenia
Evaluation of new iron chelators for clinical use.
Ovarian Neoplasms
Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy.
Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints.
Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.
Inhibition of Poly(ADP-Ribose) Polymerase Enhances Radiochemosensitivity in Cancers Proficient in DNA Double-Strand Break Repair.
Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine.
Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study.
Small Interfering RNA (siRNA)-Mediated Silencing of the M2 Subunit of Ribonucleotide Reductase: A Novel Therapeutic Strategy in Ovarian Cancer.
Pancreatic Neoplasms
A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas.
A Pilot Trial of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
Antitumor effects of KITC, a new resveratrol derivative, in AsPC-1 and BxPC-3 human pancreatic carcinoma cells.
CHK1 inhibition sensitizes pancreatic cancer cells to gemcitabine via promoting CDK-dependent DNA damage and ribonucleotide reductase downregulation.
Clinical implications of ribonucleotide reductase subunit M1 in patients with pancreatic cancer who undergo curative resection followed by adjuvant chemotherapy with gemcitabine.
Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein.
Effect of ribonucleotide reductase M1 expression on overall survival in patients with pancreatic cancer receiving gemcitabine chemotherapy: A literature-based meta-analysis.
Establishment of human pancreatic cancer gemcitabine?resistant cell line with ribonucleotide reductase overexpression.
Expression of RRM1 and its correlation with sensitivity to gemcitabine-based chemotherapy in advanced nasopharyngeal carcinoma.
Fasting cycles potentiate the efficacy of gemcitabine treatment in in vitro and in vivo pancreatic cancer models.
Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2).
Hydroxyurea and trimidox enhance the radiation effect in human pancreatic adenocarcinoma cells.
Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations.
In Situ Protein Expression of RRM1, ERCC1, and BRCA1 in Metastatic Breast Cancer Patients Treated with Gemcitabine-Based Chemotherapy.
In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy.
Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA damage and abrogation of ribonucleotide reductase induction by gemcitabine.
Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer.
MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer.
MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine based chemotherapy.
miR-211 modulates gemcitabine activity through downregulation of ribonucleotide reductase and inhibits the invasive behavior of pancreatic cancer cells.
MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells.
Prediction of a Side Effect and Efficacy of Adjuvant Chemotherapy with Gemcitabine for Post Operative Patient of Pancreatic Cancer by a Genetic Polymorphism Analysis.
Predictive and Prognostic Roles of Ribonucleotide Reductase M1 in Patients with Pancreatic Cancer Treated with Gemcitabine: A Meta-analysis.
Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone.
Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase: A novel therapeutic strategy in pancreatic cancer.
Reversible epigenetic regulation of 14-3-3? expression in acquired gemcitabine resistance by uhrf1 and DNA methyltransferase 1.
Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors.
Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines.
Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells.
The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).
Tranilast strongly sensitizes pancreatic cancer cells to gemcitabine via decreasing protein expression of ribonucleotide reductase 1.
Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2.
Parkinson Disease
Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson's disease.
Pneumonia
Molecular characterization of a ribonucleotide reductase (nrdF) gene fragment of Mycoplasma hyopneumoniae and assessment of the recombinant product as an experimental vaccine for enzootic pneumonia.
Polycythemia Vera
Hydroxyurea induced acute elevations in liver function tests.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Effect of clofarabine on apoptosis and DNA synthesis in human epithelial colon cancer cells.
Modulation of ara-CTP levels by fludarabine and hydroxyurea in leukemic cells.
Prostatic Neoplasms
A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2).
Didox (a novel ribonucleotide reductase inhibitor) overcomes Bcl-2 mediated radiation resistance in prostate cancer cell line PC-3.
Ribonucleotide reductase inhibition in the treatment of advanced prostate cancer: an experimental approach with hydroxyurea and gallium nitrate in 20 patients.
The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers.
Pseudorabies
Identification of viral polypeptides involved in pseudorabies virus ribonucleotide reductase activity.
In vivo recombination of pseudorabies virus strains in mice.
Induction of a new ribonucleotide reductase after infection of mouse L cells with pseudorabies virus.
Large and small subunits of the Aujeszky's disease virus ribonucleotide reductase: nucleotide sequence and putative structure.
Ribonucleotide reductase-deficient mutants of pseudorabies virus are avirulent for pigs and induce partial protective immunity.
Specific inhibition of herpesvirus ribonucleotide reductase by synthetic peptides.
Structural features of the ribonucleotide reductase of Aujeszky's disease virus.
The herpes simplex virus type 1 ribonucleotide reductase is a tight complex of the type alpha 2 beta 2 composed of 40K and 140K proteins, of which the latter shows multiple forms due to proteolysis.
purine-nucleoside phosphorylase deficiency
Cockayne's syndrome fibroblasts are characterized by hypersensitivity to deoxyguanosine and abnormal DNA precursor pool metabolism in response to deoxyguanosine or ultraviolet light.
Mechanisms of 2'-deoxyguanosine toxicity in mouse T-lymphoma cells with purine nucleoside phosphorylase deficiency and resistance to inhibition of ribonucleotide reductase by dGTP.
Purine nucleoside phosphorylase deficiency.
The mechanism of inhibition and "reversal" of mitogen-induced lymphocyte activation in a model of purine-nucleoside phosphorylase deficiency.
Reperfusion Injury
Control of disease by selective iron depletion: a novel therapeutic strategy utilizing iron chelators.
Respiratory Tract Infections
In vivo function of the Murid Herpesvirus-4 ribonucleotide reductase small subunit.
Retinal Diseases
The herpes simplex virus type 1 ribonucleotide reductase is required for acute retinal disease.
Retinoblastoma
Evaluation of the antitumor effects of Herpes simplex virus lacking ribonucleotide reductase in a murine retinoblastoma model.
ribonucleoside-triphosphate reductase (thioredoxin) deficiency
Deoxynucleoside Salvage in Fission Yeast Allows Rescue of Ribonucleotide Reductase Deficiency but Not Spd1-Mediated Inhibition of Replication.
Sarcoma
[Nuclear ribonucleotide reductase of cells of normal regenerating liver and sarcoma M-1 in rats]
[The ribonucleotide reductase activity of different structural elements of rat sarcoma M-1 cells]
Sarcoma, Ewing
Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma.
Inhibition of CHK1 sensitizes Ewing sarcoma cells to the ribonucleotide reductase inhibitor gemcitabine.
mTORC1/2 and Protein Translation Regulate Levels of CHK1 and the Sensitivity to CHK1 Inhibitors in Ewing Sarcoma Cells.
Seizures
Characterization of cell proliferation in the adult dentate under normal conditions and after kainate induced seizures using ribonucleotide reductase and BrdU.
Mitochondrial DNA depletion syndrome due to mutations in the RRM2B gene.
Shock, Septic
[Does nitric oxide stress exist?]
Starvation
Activities of both ribonucleotide reductase subunits, M1 and M2, decrease upon serum starvation of baby hamster kidney 21/C13 cells.
Cell cycle synchronization reveals greater G2/M-phase accumulation of lung epithelial cells exposed to titanium dioxide nanoparticles.
Deoxyribonucleotide biosynthesis in yeast (Saccharomyces cerevisiae). A ribonucleotide reductase system of sufficient activity for DNA synthesis.
In vitro and in vivo studies of a promising antileukemic thymidine analogue, 5-hydroxymethyl-2' deoxyuridine.
Making DNA without iron - induction of a manganese-dependent ribonucleotide reductase in response to iron starvation.
Regulation of the operon encoding ribonucleotide reductase in Escherichia coli: evidence for both positive and negative control.
Release of repressor control of ribonucleotide reductase by thymine starvation.
The alternative aerobic ribonucleotide reductase of Escherichia coli, NrdEF, is a manganese-dependent enzyme that enables cell replication during periods of iron starvation.
The mechanism of inhibition and "reversal" of mitogen-induced lymphocyte activation in a model of adenosine deaminase deficiency.
Stomach Neoplasms
Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro.
Ribonucleotide reductase large subunit M1 predicts poor survival due to modulation of proliferative and invasive ability of gastric cancer.
[Apoptosis mechanism of taxol combined with resveratrol on human laryngeal carcinoma Hep-2 cells].
Thrombocythemia, Essential
Hydroxyurea induced acute elevations in liver function tests.
Thyroid Cancer, Papillary
Ribonucleotide reductase large subunit M1 plays a different role in the invasion and metastasis of papillary thyroid carcinoma and undifferentiated thyroid carcinoma.
Thyroid Neoplasms
Ribonucleotide reductase large subunit M1 plays a different role in the invasion and metastasis of papillary thyroid carcinoma and undifferentiated thyroid carcinoma.
Triple Negative Breast Neoplasms
Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
Tuberculosis
A Dynamic C-Terminal Segment in the Mycobacterium tuberculosis Mn/Fe R2lox Protein Can Adopt a Helical Structure with Possible Functional Consequences.
Characterization of two genes encoding the Mycobacterium tuberculosis ribonucleotide reductase small subunit.
Crystal structure of the biologically active form of class Ib ribonucleotide reductase small subunit from Mycobacterium tuberculosis.
Design, synthesis and evaluation of peptide inhibitors of Mycobacterium tuberculosis ribonucleotide reductase.
EPR evidence of two structurally different diferric sites in Mycobacterium tuberculosis R2-2 ribonucleotide reductase protein.
Function and regulation of class I ribonucleotide reductase-encoding genes in mycobacteria.
Identification of small peptides mimicking the R2 C-terminus of Mycobacterium tuberculosis ribonucleotide reductase.
Isolation of ribonucleotide reductase from Mycobacterium tuberculosis and cloning, expression, and purification of the large subunit.
Low stability of the reduced state of Mycobacterium tuberculosis NrdH redoxin.
Novel pseudopeptides incorporating a benzodiazepine-based turn mimetic-targeting Mycobacterium tuberculosis ribonucleotide reductase.
Phototriggerable peptidomimetics for the inhibition of Mycobacterium tuberculosis ribonucleotide reductase by targeting protein-protein binding.
Reactivity studies of the tyrosyl radical in ribonucleotide reductase from Mycobacterium tuberculosis and Arabidopsis thaliana--comparison with Escherichia coli and mouse.
Ribonucleotide reduction in Mycobacterium tuberculosis: function and expression of genes encoding class Ib and class II ribonucleotide reductases.
Secondary structure conversions of Mycobacterium tuberculosis ribonucleotide reductase protein R2 under varying pH and temperature conditions.
The class Ib ribonucleotide reductase from Mycobacterium tuberculosis has two active R2F subunits.
The tyrosyl free radical of recombinant ribonucleotide reductase from Mycobacterium tuberculosis is located in a rigid hydrophobic pocket.
Urinary Bladder Neoplasms
Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.
Overexpression of ribonucleotide reductase subunit M1 protein predicts shorter survival in metastatic bladder cancer patients treated with gemcitabine-containing combination chemotherapy.
Ribonucleotide reductase M2 subunit is a novel diagnostic marker and a potential therapeutic target in bladder cancer.
RRM1 predicts clinical outcome of high-and intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy.
Uterine Cervical Neoplasms
(E)-2'-deoxy-2'-(fluoromethylene) cytidine potentiates radioresponse of two human solid tumor xenografts.
Concurrent chemoradiation in carcinoma of the uterine cervix.
Downregulation of ribonucleotide reductase subunits M2 induces apoptosis and G1 arrest of cervical cancer cells.
Gemcitabine and carboplatin demonstrate synergistic cytotoxicity in cervical cancer cells by inhibiting DNA synthesis and increasing cell apoptosis.
Long noncoding RNA LINC00958 regulates cell sensitivity to radiotherapy through RRM2 by binding to microRNA-5095 in cervical cancer.
Molecular Strategies of Deoxynucleotide Triphosphate Supply Inhibition Used in the Treatment of Gynecologic Malignancies.
Radiosensitization of Human Cervical Cancer Cells by Inhibiting Ribonucleotide Reductase: Enhanced Radiation Response at Low-Dose Rates.
Ribonucleotide reductase expression in cervical cancer: a radiation therapy oncology group translational science analysis.
Vaccinia
Acidic C terminus of vaccinia virus DNA-binding protein interacts with ribonucleotide reductase.
Allosteric regulation of vaccinia virus ribonucleotide reductase, analyzed by simultaneous monitoring of its four activities.
Amplification of the ribonucleotide reductase small subunit gene: analysis of novel joints and the mechanism of gene duplication in vaccinia virus.
Cloning of the vaccinia virus ribonucleotide reductase small subunit gene. Characterization of the gene product expressed in Escherichia coli.
Deletion of F4L (ribonucleotide reductase) in vaccinia virus produces a selective oncolytic virus and promotes anti-tumor immunity with superior safety in bladder cancer models.
Deoxyadenosine reverses hydroxyurea inhibition of vaccinia virus growth.
Differential effects of hydroxyurea upon deoxyribonucleoside triphosphate pools, analyzed with vaccinia virus ribonucleotide reductase.
Gene translocations in poxviruses: the fowlpox virus thymidine kinase gene is flanked by 15 bp direct repeats and occupies the locus which in vaccinia virus is occupied by the ribonucleotide reductase large subunit gene.
Generation of an attenuated Tiantan vaccinia virus by deletion of the ribonucleotide reductase large subunit.
Hydroxyurea-resistant vaccinia virus: overproduction of ribonucleotide reductase.
Insertional inactivation of the large subunit of ribonucleotide reductase encoded by vaccinia virus is associated with reduced virulence in vivo.
Intracellular chelation of iron by bipyridyl inhibits DNA virus replication: ribonucleotide reductase maturation as a probe of intracellular iron pools.
Mouse ribonucleotide reductase control: influence of substrate binding upon interactions with allosteric effectors.
Nucleotide sequence and molecular genetic analysis of the large subunit of ribonucleotide reductase encoded by vaccinia virus.
Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironment.
Purification, crystallization and preliminary diffraction studies of an ectromelia virus glutaredoxin.
Roles of vaccinia virus ribonucleotide reductase and glutaredoxin in DNA precursor biosynthesis.
The effect of nitric oxide on vaccinia virus-encoded ribonucleotide reductase.
The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism.
The sequences of the ribonucleotide reductase genes from African swine fever virus show considerable homology with those of the orthopoxvirus, vaccinia virus.
Vaccinia virus induces ribonucleotide reductase in primate cells.
Vaccinia virus ribonucleotide reductase expression and isolation of the recombinant large subunit.
Vaccinia virus ribonucleotide reductase. Correlation between deoxyribonucleotide supply and demand.
Vaccinia virus-encoded ribonucleotide reductase subunits are differentially required for replication and pathogenesis.
Vaccinia virus-encoded ribonucleotide reductase: sequence conservation of the gene for the small subunit and its amplification in hydroxyurea-resistant mutants.
Vaccinia virus-induced ribonucleotide reductase can be distinguished from host cell activity.
Vaginal Neoplasms
Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers.
Virus Diseases
Deletion of the varicella-zoster virus large subunit of ribonucleotide reductase impairs growth of virus in vitro.
Marine actinomycetes as bioremediators in Penaeus monodon rearing system.
Partial purification and characterization of the ribonucleotide reductase induced by herpes simplex virus infection of mammalian cells.
Potential for combined therapy with 348U87, a ribonucleotide reductase inhibitor, and acyclovir as treatment for acyclovir-resistant herpes simplex virus infection.
Ribonucleotide reductase: an important enzyme in the replication of herpes simplex virus type 1 and a target for antiviral chemotherapy.
The ribonucleotide reductase inhibitor (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731): a potential topical therapy for herpes simplex virus infection.
Vaccinia virus ribonucleotide reductase. Correlation between deoxyribonucleotide supply and demand.
Vulvar Neoplasms
LC-MS/MS assay for the quantitation of the ribonucleotide reductase inhibitor triapine in human plasma.
Waldenstrom Macroglobulinemia
Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2'-deoxyadenosine (2-CdA) and Rituximab.
Wilms Tumor
The 11p15.5 ribonucleotide reductase M1 subunit locus is not imprinted in Wilms' tumour and hepatoblastoma.
Xeroderma Pigmentosum
Altered gene expression in human cells treated with the insecticide diazinon: correlation with decreased DNA excision repair capacity.
Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery.
ERCC1 and BRCA1 mRNA expressions are associated with clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients.
Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer.
XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression.
Yellow Fever
Regulation of the ribonucleotide reductase small subunit (R2) in the yellow fever mosquito, Aedes aegypti.
Ribonucleotide reductase subunits from the yellow fever mosquito, Aedes aegypti: cloning and expression.